Articles Comprising Silk Polypeptides for Antigen Delivery - Patent application

A silk polypeptide-based antigen carrier addresses cytotoxicity and adjuvant issues in current delivery agents by providing non-cytotoxic, adjuvant-free antigen delivery that enhances cellular uptake and immune response efficacy.

JP7596354B2Active Publication Date: 2024-12-09AMSILK
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2022200396
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-06-22
Filing Date
2022-12-15
Publication Date
2024-12-09
Estimated Expiration
2037-06-13

AI Technical Summary

Technical Problem

Current antigen delivery agents are cytotoxic, poorly absorbed by cells, and often require adjuvants that can cause side effects, limiting their effectiveness and safety in immunotherapy.

Method used

Development of a single-chain polypeptide composed of a silk polypeptide and an antigen, which is non-cytotoxic and preferentially taken up by cells, eliminating the need for adjuvants and allowing for efficient antigen delivery without organic solvents or toxic substances.

Benefits of technology

The silk polypeptide-based antigen carrier achieves effective immune response induction without adjuvants, reducing side effects and enhancing antigen uptake and efficacy, suitable for therapeutic and prophylactic treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596354000001
    Figure 0007596354000001
  • Figure 0007596354000002
    Figure 0007596354000002
  • Figure 0007596354000003
    Figure 0007596354000003
Patent Text Reader

Abstract

Articles or pharmaceutical compositions for inducing an immune response and / or for use in the prophylactic and / or therapeutic treatment of disease are provided. [Solution] The present invention provides particles comprising a solid inner matrix having an outer surface, wherein both the inner matrix and the outer surface comprise a polypeptide, the polypeptide comprising (i) a silk polypeptide, (ii) an antigenic peptide or polypeptide, and (iii) an enzyme-cleavable linker, wherein the antigenic peptide or polypeptide is connected to the silk polypeptide via the enzyme-cleavable linker, and a pharmaceutical composition comprising the particles.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a polypeptide comprising a silk polypeptide and an antigen.Furthermore, the present invention relates to an article comprising said polypeptide.Furthermore, the present invention relates to a pharmaceutical composition comprising said article.In addition, the present invention relates to said article or pharmaceutical composition for use as a medicament, for inducing an immune response, and / or for use in the preventive and / or therapeutic treatment of disease. [Background technology]

[0002] Antigen delivery to animal cells, for example human cells, is important in the medical field. It has high potential in the commercial field of vaccination, for example. In addition, it is of great relevance for improving therapeutic approaches to treat animals, for example humans. Therapeutic vaccination against cancer, autoimmune diseases, mycoses, viral and bacterial infections, or Hepatitis B / C or HIV, for example, are promising targets for immunotherapeutic treatment.

[0003] Immunization by vaccination is one of the most productive tools in modern medical practice. The body's ability to defend itself against foreign pathogens depends on the body's ability to recognize and react to infectious agents once they are presented to the host's immune cells in a process known as the adaptive immune response. Currently used compositions for immunization deliver antigens together with a mixture of stabilizers, preservatives, and adjuvants. Antigens are typically protein components of bacteria or viruses. Vaccines containing antigens induce both humoral and cellular responses against the antigen. The effectiveness of such vaccinations depends heavily on the immunogenicity of the antigen, which in turn is a function of the antigen's size, molecular complexity, degree of "foreignness," and ability to be cleaved into peptides by antigen-presenting cells (APCs). Stimulated and activated by the antigen, APCs migrate to the draining lymph nodes (DLNs), where the antigen is then presented to naive T helper cells. The antigen is then presented to B cells, resulting in systemic antibody production as well as priming of memory B cells. Initial antibody production begins to wane approximately 3 weeks after primary exposure, but can be further enhanced by secondary contact with the same antigen. Therefore, booster injections are highly recommended and typically induce high concentrations of antigen-specific antibodies. Dendritic cells (DCs), as specialized antigen-presenting cells (APCs), play a key role in both innate and adaptive immunity. DCs are specialized antigen-presenting cells with the unique ability to capture and process antigens, migrate from the periphery to lymphoid organs, and present antigens to resting T cells in a major histocompatibility complex (MHC)-restricted manner.

[0004] However, one of the weaknesses of currently available antigen delivery materials is the cytotoxic effect they cause on target cells. Considering the possible therapeutic and clinical uses of delivery materials, less cytotoxic materials are needed to carry antigens to various cells without affecting their inherent signaling pathways and systems. In addition, vaccines containing antigens are often not well absorbed / internalized by cells. Therefore, there is a need for non-cytotoxic articles containing antigens that have a structure that is preferentially absorbed / internalized by cells. Furthermore, no artificial antigen carrier vehicle is known in the art that is composed of a carrier polypeptide and a single-chain polypeptide containing an antigen.

[0005] The inventors of the present patent application have for the first time created an antigen carrier article that is composed of a single-chain polypeptide comprising a silk polypeptide as a carrier polypeptide in addition to an antigen. Furthermore, the inventors of the present patent application have surprisingly found that an antigen that is part of an article, e.g., a particle, comprising a silk polypeptide, is preferentially taken up by animal cells, e.g., human cells. In this context, the inventors of the present patent application have been surprised that an article, e.g., a particle, composed mainly of silk, acts as an auxiliary material that stabilizes the antigen and makes it transportable. The article, e.g., the particle, can be degraded without a trace in an organism (e.g., the human body). Furthermore, the inventors of the present patent application have surprisingly found that the use of an adjuvant in a pharmaceutical composition comprising an antigen that is part of an article, e.g., a particle, comprising a silk polypeptide, is no longer required. The efficacy of an antigen contained in a composition without an adjuvant is at least as good or comparable to the same antigen contained in a composition with an adjuvant. The omission of an adjuvant has the positive effect that side effects and vaccine incompatibilities can be reduced and, in some cases, even avoided. In addition, the article, e.g., particle, comprising silk polypeptide and antigen is non-toxic, particularly non-cytotoxic, and non-immunogenic.The article, e.g., particle, does not require organic solvents or toxic substances and can be easily manufactured in a one-step production process.In addition, the one-step production process reduces the risk of harmful impurities or contamination, which has significant advantages in terms of documentation and regulations.The one-step production process means that no additional loading step is required after the article is formed.The one-step production process is particularly desirable because it can be easily scaled up to manufacturing scale.In addition, the antigen is precisely defined by the genetic code in the polypeptide, and therefore is not degraded during the otherwise required loading procedure. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] International Publication No. 2006 / 008163 Brochure A2 [Patent Document 2] International Publication No. 2011 / 120690 Brochure A2 [Patent Document 3] International Publication No. 2007 / 014755 Brochure A1 [Non-patent literature]

[0007] [Non-Patent Document 1] “A multilingual glossary of biotechnological terms: (IUPAC Recommendations)”, edited by Leuenberger, HGW, Nagel, B. and Kolbl, H. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland). [Non-Patent Document 2] Remington's Pharmaceutical Sciences, Mack Publishing Co. (ed. AR Gennaro, 1985) Summary of the Invention [Means for solving the problem]

[0008] In a first aspect, the present invention provides a method for producing a composition comprising the steps of: (i) a silk polypeptide, and (ii) Antigen The present invention relates to a polypeptide comprising:

[0009] In a second aspect, the present invention relates to a nucleic acid molecule encoding a polypeptide of the first aspect.

[0010] In a third aspect, the present invention provides a method for producing a composition comprising the steps of: (a) a method of producing a polypeptide comprising the step of expressing a nucleic acid molecule of the second aspect in a cell, thereby producing said polypeptide in said cell.

[0011] In a fourth aspect, the present invention relates to an article comprising a polypeptide of the first aspect.

[0012] In a fifth aspect, the present invention provides a method for producing a composition comprising the steps of: (a) providing an aqueous solution comprising a polypeptide of the first aspect; (b) forming an article out of / from the solution provided in (a).

[0013] In a sixth aspect, the present invention relates to a pharmaceutical composition comprising the article of the fourth aspect.

[0014] In a seventh aspect, the present invention relates to the article of the fourth aspect or the pharmaceutical composition of the sixth aspect for use as a medicament.

[0015] In an eighth aspect, the present invention relates to the article of the fourth aspect or the pharmaceutical composition of the sixth aspect for inducing an immune response.

[0016] In a ninth aspect, the present invention relates to an article of the fourth aspect or a pharmaceutical composition of the sixth aspect for use in the prophylactic and / or therapeutic treatment of a disease.

[0017] In a tenth aspect, the present invention relates to a method of delivering an antigen to a cell comprising administering to a subject an article of the fourth aspect or a pharmaceutical composition of the sixth aspect.

[0018] In an eleventh aspect, the present invention relates to a method of inducing an immune response in a subject comprising administering to the subject an article of the fourth aspect or a pharmaceutical composition of the sixth aspect.

[0019] In a twelfth aspect, the present invention relates to a method for prophylactic and / or therapeutic treatment in a subject comprising administering to the subject an article of the fourth aspect or a pharmaceutical composition of the sixth aspect.

[0020] In a thirteenth aspect, the present invention relates to a method of stimulating, priming and / or expanding T cells in a subject comprising administering to the subject an article of the fourth aspect or a pharmaceutical composition of the sixth aspect.

[0021] This summary of the invention does not necessarily describe all features of the invention, as other embodiments will become apparent from a review of the ensuing detailed description.

[0022] The following figures and examples are merely illustrative of the present invention and should not be construed in any way as limiting the scope of the invention as intended by the appended claims. [Brief description of the drawings]

[0023] [Figure 1]Figure 1 shows that none of the spider silk particles of the invention induces BMDC cytotoxicity in vitro. Figure 1A shows dot plots from flow cytometry with propidium iodide (PI) and annexin V. BMDCs (5x104 cells / well) were cultured with spider silk particles at 505 μg particles / mL (=10 μg SIINFEKL (SEQ ID NO: 11) / mL). After 24 hours of incubation, BMDC viability was assessed by flow cytometry and MTT assay. (A) Representative dot plots from flow cytometry with propidium iodide (PI) and annexin V. (B) Scheme of the gating strategy to quantify live healthy cells (annexin V- / PI-). (C) Percentage of live healthy cells (annexin V- / PI-). (D) Optical density (OD) at 570 nm from MTT assay, which correlates with formazan production. Cell-free conditions (vehicle only) served as control. nd: not performed. Asterisks (****, P<0.0001) indicate significant differences from the untreated control group using one-way ANOVA followed by Dunnett's multiple comparison test (C and D). Each bar represents the mean ± SEM of three independent experiments performed in duplicate (except for panel C, C16-SIIN, which was tested once in duplicate). Vehicle only served as control. Untreated: untreated control group; SIIN: SIINFEKL (SEQ ID NO: 11) peptide alone; C16: native C16 particles; C16-SIIN; C16-CathBseq-SIIN, C16-CathSseq-SIIN hybrid protein particles. [Diagram 2]Figure 2 shows that spider silk particles of the present invention do not induce BMDC immunological activation in vitro. Figure 2A shows the median fluorescence intensity (MFI) of BMDC surface activation markers MHC I and MHC II of BMDC cells cultured with SIIN, CathBseq-SIIN, and C16-CathSseq-SIIN compared to untreated samples. Figure 2B shows cytokine quantification by ELISA. TLR7 agonist, R848 (R8), was used as a positive control. BMDCs (5x104 cells / well) were cultured with spider silk particles at 50 μg particles / mL. After 24 hours of incubation, BMDCs were analyzed by flow cytometry, while supernatants were collected for cytokine quantification. (A) Median fluorescence intensity (MFI) of BMDC surface activation markers: fold change compared to untreated samples. (B) Cytokine quantification by ELISA. A TLR7 agonist, R848 (R8), was used as a positive control (0.25 μg / mL). Asterisks (***, P<0.001) indicate significant differences from the untreated control group using one-way ANOVA followed by Dunnett's multiple comparison test. Each bar represents the mean ± SEM of four independent experiments performed in duplicate. [Diagram 3]Spider silk particles are efficiently taken up by antigen-presenting cells. Figure 3A shows the uptake of C16 particles without SIIN (C16), C16 hybrid particles C16-SIIN, C16 hybrid particles with cathepsin B cleavage site (C16-CathBseq-SIIN), and C16 hybrid particles with cathepsin S cleavage site (C16-CathSseq-SIIN). Untreated cells (untreated) and SIIN polypeptide (SIIN) serve as controls. Figure 3B shows the percentage of FITC-positive cells determined in defined immune cell populations: T cells (CD3+), dendritic cells (CD11c+CD11b+), and monocytes / macrophages (CD11c-CD11b+) compared to untreated cells. (A) BMDCs (5x104 cells / well) were cultured with 50 μg particles / mL of FITC-labeled spider silk particles. After 24 h of incubation, BMDCs were isolated for flow cytometry analysis. The percentage of FITC-positive cells within the BMDC (CD11c+) population was determined. Each bar represents the mean ± SEM of two independent experiments performed in duplicate (except for C16-SIIN, which was tested once in duplicate). (B) Freshly isolated splenocytes (5 × 104 cells / well) were cultured with FITC-labeled spider silk particles for 6 h. After 6 h of incubation, cells were analyzed by flow cytometry. The percentage of FITC-positive cells was determined in defined immune cell populations: T cells (CD3+), dendritic cells (CD11c+CD11b+), and monocytes / macrophages (CD11c-CD11b+). Graph depicts one representative experiment out of three. Each experiment was performed in duplicate. [Figure 4]Figure 4 shows that cathepsin S sequence is most effective in inducing SIINFEKL (SEQ ID NO: 11)-dependent in vitro T cell proliferation. Figure 4 shows the percentage of proliferative CD8 T cells within the T cell population (CD3+CD8+). The percentage of proliferative CD8 T cells exposed to BMDC cells with C16 CathSseq-SIINFEKL particles and C16 CathBseq-SIINFEKL particles was significantly higher compared to untreated controls. The percentage of proliferative CD8 T cells exposed to BMDC cells with C16 CathSseq-SIINFEKL particles was even significantly higher than the percentage of proliferative CD8 T cells exposed to BMDC cells with C16 CathBseq-SIINFEKL particles. BMDCs (5x104 cells / well) were cultured with spider silk particles at 50 μg particles / mL. R848 (0.25 μg / mL) was used as an adjuvant for BMDC activation. After 24 h of incubation, CFSE-labeled CD3+CD8+ OT-I cells (105 cells / well) were added. After 3 days of co-culture, cells were analyzed by flow cytometry. Percentage of proliferating cells within the T cell population (CD3+CD8+). Each bar represents the mean ± SEM of two independent experiments performed in quadruplicate. Asterisks (**, P<0.01) indicate significant differences between R848-treated groups using two-way ANOVA followed by Tukey's multiple comparison test. [Diagram 5]Hybrid spider silk particles accumulate in the draining lymph nodes in vivo. Figure 5A shows the number of FITC-positive cells (containing FITC-labeled C16-CathSseq-SIINFEKL particles) in the draining lymph nodes (DLN) of three FITC particle-treated mice compared to a control group of three PBS-treated mice in several tissues (DLN, non-DLN, and spleen). FITC-labeled C16-CathSseq-SIINFEKL particles were injected subcutaneously into the right flank of three mice (505 μg particles in 100 μL PBS per mouse). PBS was used as a negative control. After 24 hours, the ipsilateral draining lymph nodes (DLN), contralateral lymph nodes (non-DLN), and spleen were isolated for flow cytometry analysis. (A) Number of FITC-positive cells in different lymphoid organs. (B) Percentage of FITC-positive cells within defined immune cell populations. Each dot represents one mouse. Bars represent the mean ± SEM. Asterisks (***, P<0.001) indicate significant differences when comparing FITC particle-treated mice with PBS-treated mice using two-way ANOVA followed by Bonferroni's multiple comparison test. Figure 5A shows that C16-CathSseq-SIINFEKL particles accumulated in the draining lymph nodes (DLN) after administration. The results shown in Figure 5B point out a trend towards uptake by dendritic cells (CD11c+CD11b+) rather than by macrophages (CD11c-CD11b+) or leukocytes (CD11b-). [Figure 6]SIINFEKL (SEQ ID NO: 11)-containing spider silk particles induce antigen-dependent T cell proliferation in vivo. FIG. 6 shows the proliferation of CD8 T cells in mice immunized with C16-CathSseq-SIINFEKL particles. The proliferation of CD8 T cells was significantly higher without R848 adjuvant. Mice were intravenously injected with 106 CFSE-labeled CD3+CD8+ OT-I cells in 100 μL PBS (each dot represents one mouse). 18 hours later, mice were vaccinated with spider silk particles (505 μg particles in 100 μL PBS per mouse). R848 (25 μg) was used as adjuvant. Three days after vaccination, DLNs were isolated for flow cytometry analysis to determine the proliferation of CD3+CD8+ CFSE-labeled OT-I cells. Each dot represents one mouse. Bars represent the mean ± SEM. Asterisks (****, P<0.0001) indicate significant differences from R848-treated controls using one-way ANOVA followed by Dunnett's multiple comparison test. CD8 T cell proliferation was higher without R848 adjuvant. It can be shown that C16-CathSseq-SIINFEKL protein particles can induce similar and higher levels of proliferating CD8+ T cells with or without the use of immunostimulatory adjuvant R848, respectively. [Figure 7]Figure 1 shows the incubation of C16 particles, C16-CathB-SIINFEKL and C16-CathS-SIINFEKL with cathepsin S and cathepsin B enzymes in vitro. Differential release of antigen with different cathepsin enzymes. The sequence LPGSIINFEKLG (SEQ ID NO: 17) was released from C16-CathS-SIINFEKL hybrid protein particles, while the sequence IGSIINFEKLG (SEQ ID NO: 16) was released from C16-CathB-SIINFEKL hybrid protein particles. The sequence contains SIINFEKL (SEQ ID NO: 11). Data are the mean and SD (standard deviation) of three independent replicates. Cathepsin S enzyme shows better cleavage of SIINFEKL (SEQ ID NO: 11) peptide from both C16 hybrid protein particles than cathepsin B. Cathepsin S also cleaves the SIINFEKL (SEQ ID NO: 11) peptide from particles designed for release by cathepsin B. (A) eADF4(C16) hybrid protein particles incubated with cathepsin S enzyme for 96 hours. (B) eADF4(C16) hybrid protein particles incubated with cathepsin B enzyme for 96 hours. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] definition Before the present invention is described in detail below, it should be understood that this invention is not limited to the specific methodology, protocols, and reagents described herein, as these may vary. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments only, and is not intended to limit the scope of the present invention, which will be limited only by the appended claims. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0025] Preferably, the terms used herein are defined as set forth in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", Leuenberger, HGW, Nagel, B. and Kolbl, H. (eds.) (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland).

[0026] Several documents are cited throughout the text of this specification. Whether above or below, each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, GenBank accession number submissions, etc.) is incorporated herein by reference in its entirety. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such disclosure by reason of prior invention. In the event of a conflict between a definition or teaching of such incorporated reference and a definition or teaching recited herein, the text of this specification shall control.

[0027] The term "comprise" or inflections such as "comprises" or "comprising" according to the present invention means the inclusion of a stated integer or group of integers, but does not mean the exclusion of any other integer or group of integers. The term "consisting essentially of" according to the present invention means the inclusion of a stated integer or group of integers, while excluding modifications or other integers that would substantially affect or change the stated integer. The term "consisting of" or inflections such as "consisting of" according to the present invention means the inclusion of a stated integer or group of integers, and the exclusion of any other integer or group of integers.

[0028] As used in the context of describing the present invention (particularly in the context of the claims), the terms "a," "an," "the," and similar designations are to be construed to cover both the singular and the plural, unless otherwise indicated in the specification or clearly contradicted by context.

[0029] The terms "polypeptide" and "protein" are used interchangeably in the context of the present invention. They refer to long peptide-linked chains of amino acids, e.g., typically 40 amino acids in length or longer.

[0030] As used herein, the term "peptide" refers to short peptide-linked chains of amino acids, eg, typically less than about 40 amino acids in length, more typically less than about 30 amino acids in length.

[0031] The terms "fusion protein" or "hybrid protein" (literally made of parts from different sources) are used interchangeably in the context of the present invention. They refer to proteins that are created through the joining of two or more genes that originally coded for separate proteins / peptides. Translation of this fusion gene results in a single polypeptide chain that has functional properties derived from each of the original proteins / peptides.

[0032] The terms "recombinant fusion protein" or "recombinant hybrid protein" are used interchangeably in the context of the present invention. They refer to a single polypeptide chain that is artificially produced by recombinant DNA technology.

[0033] In one embodiment, the polypeptide of the present invention is a fusion or hybrid polypeptide comprising a silk polypeptide and an antigen.In one preferred embodiment, the polypeptide of the present invention is a fusion or hybrid polypeptide comprising a silk polypeptide, an antigen and an enzyme-cleavable linker, wherein the antigen is attached to the silk polypeptide via the enzyme-cleavable linker, or the enzyme-cleavable linker is located between the silk polypeptide and the antigen.The sequence of the enzyme-cleavable linker can be modified by adding additional non-functional amino acids.

[0034] As used herein, the term "silk polypeptide" refers to a polypeptide that exhibits a completely unusual amino acid composition compared to other polypeptides. In particular, silk polypeptides have large amounts of hydrophobic amino acids such as glycine or alanine, but no (or only very small amounts of) tryptophan, for example. In addition, silk polypeptides contain highly repeated amino acid sequences or repeat units (repeat units, modules), especially in their large core domains. Based on DNA analysis, it has been shown that all silk polypeptides are chains of repeat units that further contain a limited set of distinct shorter peptide motifs. The expressions "peptide motif" and "consensus sequence" can be used interchangeably herein. In general, silk consensus sequences fall into four major categories: GPGXX, GGX, A, and B. x , or (GA) nand spacers. These categories of peptide motifs in silk polypeptides have been assigned structural roles. For example, it has been suggested that the GPGXX motif is involved in the β-turn spiral, possibly imparting elasticity. The GGX motif is known to be involved in the glycine-rich 31-helix. Both the GPGXX motif and the GGX motif are thought to be involved in the formation of an amorphous matrix that connects crystalline regions, thereby imparting elasticity to the fiber. The alanine-rich motifs typically contain 6-9 residues and have been found to form crystalline β-sheets. The spacers typically contain charged groups and separate the repeated peptide motifs into clusters. Preferably, the silk polypeptide is a spider silk polypeptide. More preferably, the silk polypeptide, e.g., the spider silk polypeptide, is a recombinant polypeptide.

[0035] As used herein, the term "antigen" refers to a molecule that contains an epitope against which an immune response can be generated. The term "antigen" includes proteins or peptides. The term "antigen" also includes molecules that become antigenic only through conversion (e.g., intermediate in the molecule or by completion with a body protein). Antigens are preferably presentable by cells of the immune system, such as antigen-presenting cells (APCs) like dendritic cells (DCs) or macrophages. In addition, the antigen or its processing products are preferably recognizable by T-cell or B-cell receptors or by immunoglobulin molecules such as antibodies. The antigen may be a disease-related antigen, such as a tumor antigen, a viral antigen, or a bacterial antigen.

[0036] In the context of the present invention, the term "disease-associated antigen" is used in its broadest sense to refer to any antigen associated with a disease. A disease-associated antigen is a molecule that contains an epitope that will stimulate the host's immune system to generate a cellular antigen-specific immune response and / or a humoral antibody response against the disease. Thus, disease-associated antigens can be used for therapeutic purposes. Disease-associated antigens are preferably associated with infection by microorganisms, typically microbial antigens, or associated with cancer, typically tumors.

[0037] As used herein, the term "disease" refers to an abnormal condition that affects an individual's body. A disease is often interpreted as a medical condition with certain symptoms and signs. A disease may be caused by an agent from an external source in nature, such as an infectious disease, or it may be caused by an internal dysfunction, such as an autoimmune disease. In humans, "disease" is often used more broadly to refer to any condition that causes pain, impairment, distress, social problems, or death to the affected individual, or similar problems for those who come into contact with that individual. In this broader sense, it sometimes includes injury, disability, disorder, syndrome, infection, single symptoms, deviant behavior, and atypical variations of structure and function, although in other contexts and for other purposes, these may be considered as distinct categories. A disease usually affects an individual not only physically, but also emotionally, because suffering from and living with many diseases can change a person's outlook on life and his or her personality.

[0038] As mentioned above, the disease may be an infectious disease or an autoimmune disease. The disease may also be a cancer disease, or simply cancer.

[0039] As used herein, the term "infectious disease" refers to any disease that can be transmitted from individual to individual or organism to organism, and is caused by microbial agents (e.g., cold). Infectious diseases are known in the art, and include, for example, viral diseases, bacterial diseases, or parasitic diseases. Said diseases are caused by viruses, bacteria, and parasites, respectively. In this regard, infectious diseases can be, for example, hepatitis, sexually transmitted diseases (e.g., chlamydia or gonorrhea), tuberculosis, HIV / Acquired Immune Deficiency Syndrome (AIDS), diphtheria, hepatitis B, hepatitis C, cholera, severe acute respiratory syndrome (SARS), avian influenza, and influenza.

[0040] As used herein, the term "autoimmune disease" refers to any disease in which the body develops an immunogenic (i.e., immune system) response against some component of its own tissues. In other words, the immune system loses the ability to recognize some tissue or system in the body as self, and targets and attacks it as if it were foreign. Autoimmune diseases can be classified into those in which one organ is primarily affected (e.g., hemolytic anemia and autoimmune thyroiditis) and those in which the autoimmune disease process is spread through many tissues (e.g., systemic lupus erythematosus). For example, multiple sclerosis is thought to be caused by T cells attacking the sheaths surrounding nerve fibers in the brain and spinal cord. This results in loss of coordination, weakness, and blurred vision. Autoimmune diseases are known in the art and include, by way of example, Hashimoto's thyroiditis, Graves' disease, lupus, multiple sclerosis, rheumatoid arthritis, hemolytic anemia, autoimmune thyroiditis, systemic lupus erythematosus, celiac disease, Crohn's disease, colitis, diabetes, scleroderma, psoriasis, and others.

[0041] As used herein, the term "cancer disease" or "cancer" refers to or describes a physiological condition in an individual that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More specifically, examples of such cancers include bone cancer, blood cancer, lung cancer, liver cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, prostate cancer, uterine cancer, carcinoma of the genital and reproductive organs, Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the bladder, cancer of the kidney, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), neuroectodermal cancer, tumors of the spinal axis, glioma, meningioma, and pituitary adenoma. The term "cancer" according to the present invention also includes cancer metastasis.

[0042] As mentioned above, the antigen may be a tumor antigen, a viral antigen, or a bacterial antigen.

[0043] As used herein, the term "tumor antigen" refers to the components of cancer cells, which can be derived from cytoplasm, cell surface, and cell nucleus.In particular, it refers to those antigens that are preferably produced in large amounts, intracellularly, or as surface antigens on tumor cells.Examples of tumor antigens include, but are not limited to, HER2, EGFR, VEGF, CAMPATH1-antigen, CD22, CA-125, HLA-DR, Hodgkin's lymphoma, or mucin-1.

[0044] As used herein, the term "viral antigen" refers to any viral component that has antigenic properties, i.e., is capable of eliciting an immune response in an individual. A viral antigen may be a viral ribonucleoprotein or an envelope protein.

[0045] As used herein, the term "microbial antigen" refers to any microbial component that has antigenic properties, i.e., is capable of eliciting an immune response in an individual.

[0046] As used herein, the term "bacterial antigen" refers to any bacterial component that has antigenic properties, i.e., is capable of eliciting an immune response in an individual. Bacterial antigens can be derived from the bacterial cell wall or cell membrane.

[0047] As used herein, the term "fungal antigen" refers to any fungal component that has antigenic properties, i.e., is capable of eliciting an immune response in an individual.

[0048] As used herein, the term "animal parasite antigen" refers to any component of an animal parasite that has antigenic properties, i.e., is capable of eliciting an immune response in an individual. The parasite may be a flea, a louse, or a worm.

[0049] As used herein, the term "immune response" refers to the reaction of the immune system against an immunogenic organism, such as a bacterium, a virus, a cell, or a substance. The term "immune response" includes innate and adaptive immune responses. Preferably, the immune response is related to the activation of immune cells, the induction of cytokine biosynthesis, and / or antibody production. The immune response induced by the article of the present invention (or, more specifically, by the antigen of which it is a part) comprises the steps of activation of antigen-presenting cells (APCs), such as dendritic cells (DCs) and / or macrophages, presentation of the antigen or a fragment thereof by said antigen-presenting cells, and activation of cytotoxic T cells by this presentation.

[0050] As used herein, the term "immune cell" refers to a cell of the immune system that is involved in defending an individual's body. The term "immune cell" encompasses specific types of immune cells and their precursors, including white blood cells, including macrophages, monocytes (precursors of macrophages), granulocytes such as neutrophils, eosinophils, and basophils, dendritic cells, mast cells, and lymphocytes such as B cells, T cells, and natural killer (NK) cells. Macrophages, monocytes (precursors of macrophages), neutrophils, dendritic cells (DC), and mast cells are phagocytes.

[0051] As used herein, the term "antigen-presenting cell (APC)" refers to a cell or a variety of cells that can display, acquire and / or present at least one antigen or antigen fragment on its cell surface (or on its cell surface). Antigen-presenting cells can be distinguished in professional and non-professional antigen-presenting cells.

[0052] As used herein, the term "professional antigen-presenting cells" refers to antigen-presenting cells that constitutively express major histocompatibility complex class II (MHC class II) molecules that are required for interaction with naive T cells. If T cells interact with the MHC class II molecule complex on the membrane of antigen-presenting cells, the antigen-presenting cells produce costimulatory molecules that induce T cell activation. Professional antigen-presenting cells include dendritic cells (DCs) and macrophages.

[0053] As used herein, the term "non-professional antigen-presenting cells" refers to antigen-presenting cells that do not constitutively express MHC class II molecules, but do so upon stimulation with certain cytokines, such as interferon-gamma. Exemplary non-professional antigen-presenting cells include fibroblasts, thymic epithelial cells, thyroid epithelial cells, glial cells, pancreatic beta cells, or vascular endothelial cells.

[0054] As used herein, the term "dendritic cells (DC)" refers to another subtype of phagocytes belonging to the class of antigen-presenting cells (APCs). Preferably, dendritic cells are derived from hematopoietic bone marrow progenitors. These progenitors are initially transformed into immature dendritic cells. These immature cells are characterized by high phagocytic activity and low T cell activation potential. Immature dendritic cells constantly sample the surrounding environment for pathogens, such as viruses and bacteria. Once they come into contact with a presentable antigen, they activate into mature dendritic cells and begin to migrate to the spleen or lymph nodes. Immature dendritic cells phagocytose pathogens, break down their proteins into small pieces, and upon maturation, present them on the cell surface using MHC molecules. At the same time, they upregulate cell surface receptors that act as co-receptors in T cell activation, such as CD80, CD86, and CD40, which greatly enhance their ability to activate T cells. They also upregulate CCR7, a chemotactic receptor that induces dendritic cells to migrate to the spleen through bloodstream or to lymph nodes through lymphatic system. Here, they act as antigen-presenting cells and activate helper T cells and killer T cells, as well as B cells, by presenting antigens with non-antigen-specific costimulatory signals. Thus, dendritic cells can actively induce T cell or B cell-related immune responses. Preferably, the dendritic cells are splenic dendritic cells.

[0055] As used herein, the term "macrophage" refers to a subgroup of phagocytes generated by differentiation of monocytes. Macrophages activated by inflammation, immune cytokines, or microbial products non-specifically phagocytose and kill foreign pathogens within the macrophage by hydrolytic and oxidative attack, resulting in the degradation of the pathogen. Peptides from degraded proteins are displayed on the macrophage cell surface, where they can be recognized by T cells, and they can directly interact with antibodies on the B cell surface, resulting in T cell and B cell activation and further stimulation of the immune response. Macrophages belong to a class of antigen-presenting cells (APCs). Preferably, the macrophages are splenic macrophages.

[0056] As used herein, the term "T cell" or "T lymphocyte" refers to a type of lymphocyte that plays a central role in cell-mediated immunity. T cells or T lymphocytes can be distinguished from other lymphocytes, such as B cells and natural killer (NK) cells, by the presence of a T cell receptor (TCR) on their cell surface. They do not have antigen-presenting properties (or rather, they require B cells or NK cells for their antigen-presenting properties). They are called T cells because they mature in the thymus. T cells are capable of recognizing antigens when displayed on the surface or matrix of antigen-presenting cells, together with one or more MHC molecules or one or more non-classical MHC molecules.

[0057] As used herein, the term "stimulating T cells" or "stimulation of T cells" refers to the induction or activation of a T cell response by a primary signal, such as by interaction with an antigen-MHC class II complex through a T cell antigen receptor. The term also includes co-stimulation of T cells, such as through cytokines (e.g., CD80 or CD86 proteins). A T cell is activated once the T cell has undergone a primary signaling event that initiates an immune response by the T cell.

[0058] As used herein, the term "priming a T cell" refers to induction of an initial contact of a T cell with its specific antigen (e.g., by a dendritic cell (DC) presenting the antigen to the T cell), which causes the differentiation of the T cell into an effector T cell (e.g., a cytotoxic T cell or a T helper cell).

[0059] As used herein, the term "expanding T cells" or "T cell expansion" refers to an increase in the number of T cells, preferably T cells that specifically recognize an antigen. Preferably, the number of T cells that specifically recognize the antigen or antigen processing product contained in the article of the invention is increased. The antigen or antigen processing product is preferably presented in the context of an MHC molecule, such as on the surface of an antigen presenting cell (APC) such as a dendritic cell (DC) or macrophage.

[0060] As used herein, the term "immunotherapy" refers to the treatment of a disease or condition by inducing, enhancing, or suppressing an immune response. Immunotherapies designed to induce or amplify an immune response are classified as activating immunotherapies, while immunotherapies that reduce or suppress an immune response are classified as suppressing immunotherapies. The term "immunotherapy" includes antigen immunization or vaccination, as well as tumor immunization or vaccination. The term "immunotherapy" also refers to the manipulation of the immune response such that an inappropriate immune response is modulated to a more appropriate immune response in the context of autoimmune diseases such as rheumatoid arthritis, allergies, diabetes, or multiple sclerosis.

[0061] As used herein, the term "immunization" or "vaccination" describes the process of administering an antigen to an individual with the goal of inducing an immune response, e.g., for therapeutic or prophylactic reasons.

[0062] As used herein, the term "therapeutic treatment" refers to any treatment that improves the health and / or extends (increases) the lifespan of an individual. Said treatment may eliminate disease in an individual, prevent, inhibit or delay the onset of disease in an individual, reduce the frequency or severity of symptoms in an individual, and / or reduce recurrence in an individual currently suffering from or previously suffering from a disease.

[0063] As used herein, the term "prophylactic treatment" or "preventative treatment" relates to any treatment intended to prevent a disease from occurring in an individual. The terms "prophylactic treatment" or "preventative treatment" are used interchangeably herein.

[0064] As used herein, the terms "protect", "prevent", "prophylactic", "preventive" or "protective" refer to the prevention and / or treatment of the development and / or spread of a disease, e.g., a tumor, in an individual. For example, prophylactic administration of an immunotherapy, e.g., by administering an article or pharmaceutical composition of the present invention, can protect the recipient individual from the development of a tumor. For example, therapeutic administration of an immunotherapy, e.g., by administering an article or pharmaceutical composition of the present invention, can result in the cessation of the development of a disease, e.g., the inhibition of tumor progression / growth. This includes the slowing down of tumor progression / growth, particularly the disruption of tumor progression, which preferably results in the elimination of the tumor. Therapeutic administration of an immunotherapy can protect an individual from intrametastasis or metastasis of an existing tumor.

[0065] The terms "individual" and "subject" are used interchangeably in the context of the present invention. An individual or subject may be healthy, afflicted with a disease or disorder (e.g., cancer), or susceptible to a disease or disorder (e.g., cancer). An individual or subject may be an animal, such as a human. Preferably, an individual or subject is a human or another mammal (e.g., a mouse, a rat, a rabbit, a dog, a cat, a cow, a pig, a sheep, a horse, or a primate). Unless otherwise specified, the terms "individual" and "subject" do not denote a particular age, and thus include adults, elderly people, children, and newborns. An "individual" or "subject" may be a "patient".

[0066] As used herein, the term "patient" refers to an individual or subject that is afflicted, i.e., suffering from a disease or disorder. The patient may be an animal, e.g., a human. Preferably, the animal is a human or another mammal (e.g., a mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, or primate).

[0067] The article of the present invention can be administered in the form of any suitable pharmaceutical composition. The pharmaceutical composition can further comprise an adjuvant, a pharma- ceutically acceptable carrier, a diluent, and / or an excipient. The pharmaceutical composition is useful for treating, preventing, or reducing the severity of a disease or disorder. It can be administered locally or systemically, preferably systemically.

[0068] As used herein, the term "systemic administration" refers to administration of the article of the invention (or more specifically, the antigen contained therein) such that the article is distributed broadly throughout an individual's body in significant quantities and produces a biological effect. Typical systemic administration routes include administration by direct introduction of the article into the vascular system, or oral, pulmonary, or intramuscular administration, where the article is absorbed, enters the vascular system, and is carried via the blood to one or more desired sites.

[0069] Systemic administration can be by parenteral administration. As used herein, the term "parenteral administration" refers to administration of the article of the present invention such that the article does not pass through the intestine. The term "parenteral administration" includes, but is not limited to, intravenous administration, subcutaneous administration, intradermal administration, or intraarterial administration.

[0070] As mentioned above, the pharmaceutical composition of the present invention may include an adjuvant. As used herein, the term "adjuvant" refers to a compound that, when administered to an individual in combination with an antigen or antigenic peptide, prolongs, enhances, or accelerates the immune response. Adjuvants are assumed to exert their biological activity by one or more mechanisms, including increasing the surface of the antigen, prolonging the retention of the antigen in the body, delaying antigen release, targeting the antigen to macrophages, increasing the uptake of the antigen, enhancing antigen processing, stimulating cytokine release, stimulating and activating immune cells such as B cells, macrophages, dendritic cells, T cells, and non-specific activation of immune cells. Adjuvants include a heterogeneous group of compounds, such as oil emulsions (e.g., Freund's adjuvant), mineral compounds (such as alum), bacterial products (such as Bordetella pertussis toxin), or immunostimulatory complexes. Examples of adjuvants include, but are not limited to, saponin, incomplete Freund's adjuvant, complete Freund's adjuvant, tocopherol, or aluminum.However, adjuvants may also have negative side effects.For example, aluminum salts may cause severe local and systemic side effects, including sterility tumors, eosinophilia, and fasciitis, but fortunately, most of the more severe side effects are relatively rare.In addition, there is also public concern about the possible role of aluminum in neurodegenerative diseases such as Alzheimer's disease.As a result, there is a large unmet need for safer and more effective adjuvants suitable for human use.If the use of adjuvants is redundant, it would be better.

[0071] The pharmaceutical compositions according to the present invention are generally applied in "pharmaceutical effective amounts". As used herein, the term "pharmaceutical effective amount" refers to an amount that achieves the desired reaction or the desired effect, either alone or together with further administration. In the case of the treatment of a particular disease, the desired reaction is preferably related to the inhibition of the course of the disease. This includes slowing down the progression of the disease, and in particular hindering or reversing the progression of the disease. The desired reaction in the treatment of a disease can also be the delay of the onset of the disease, or the prevention of onset. The effective amount of the article or composition described herein depends on the condition to be treated, the severity of the disease, the individual parameters of the patient / subject, including age, physiological state, size, and weight, the duration of the treatment, the type of concomitant treatment (if any), the specific route of administration, and similar factors. Thus, the dose of the article or composition described herein can depend on various such parameters. If the response in the patient / subject is insufficient with the initial dose, a higher dose (or a more effective dose achieved by a different, more localized route of administration) can be used.

[0072] As mentioned above, the pharmaceutical compositions of the present invention may further comprise a pharma- ceutically acceptable carrier, diluent, and / or excipient.

[0073] As used herein, the term "excipient" is intended to refer to any substance in a pharmaceutical composition that is not an active ingredient, such as a binder, lubricant, thickener, surface active agent, preservative, emulsifier, buffer, flavoring agent, or coloring agent.

[0074] As used herein, the term "diluent" refers to an agent that dilutes and / or thins. Additionally, the term "diluent" includes solutions, suspensions (e.g., liquid or solid suspensions), and / or media.

[0075] As used herein, the term "carrier" refers to one or more compatible solid or liquid fillers suitable for administration, for example to humans.The term "carrier" refers to a natural or synthetic organic or inorganic component that is combined with active component to facilitate application of active component.Preferably, the carrier component is sterile, liquid such as water or oil, including those derived from mineral oil, animal or plant oil such as peanut oil, soybean oil, sesame oil, sunflower oil, etc.Saline solution and aqueous dextrose and glycerin solution can also be used as aqueous carrier compound.

[0076] Pharmaceutically acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field and described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A.R. Gennaro, ed., 1985). Examples of suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter, etc. Examples of suitable diluents include ethanol, glycerol, and water.

[0077] Pharmaceutical carriers, diluents, and / or excipients may be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions of the present invention may contain any suitable binder, lubricant, suspending agent, coating agent, and / or solubilizing agent as, or in addition to, the carrier, excipient, or diluent. Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flowing lactose, beta-lactose, corn syrup, natural and synthetic gums such as gum arabic, gum tragacanth, or sodium alginate, carboxymethylcellulose, and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Preservatives, stabilizers, dyes, and even flavoring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may also be used.

[0078] In the context of the present invention, the term "particle" refers to a structured entity formed by a polypeptide. According to the present invention, the structured entity formed by a polypeptide comprises a silk polypeptide and an antigen. In one embodiment, the particle comprises a fusion or hybrid polypeptide comprising a silk polypeptide and an antigen. In one preferred embodiment, the particle comprises a fusion or hybrid polypeptide comprising a silk polypeptide, an antigen, and an enzyme-cleavable linker, wherein the antigen is connected to the silk polypeptide via the enzyme-cleavable linker or the enzyme-cleavable linker is located between the silk polypeptide and the antigen. As used herein, the term "particle" further refers to a micro- or nano-sized spherical structure that may be formed by protein aggregation under certain conditions. It is preferred that the particle comprises or consists of a matrix and a surface. Preferably, the matrix is ​​homogeneous and more preferably does not comprise any clearly visible inclusions (e.g., as determined by electron microscopy). In this respect, it should be noted that the inclusions may be air and polypeptides that are not associated with the polypeptide of the present invention. As used herein, the term "surface" defines the outer spherical surface of a particle, including those spherical sections that are directly exposed to the surrounding space, e.g., the surrounding medium or bodily fluids. Although a particle appears smooth and uniform, its surface at a submicroscopic level exhibits a thin mantle with irregular and diffuse structure. Thus, the surface follows the contour of the outermost layer of the particle that shares an interface with the surrounding space, e.g., the surrounding medium or bodily fluids.

[0079] As used herein, the term "matrix" defines the inner sphere of a particle, which is not the surface, i.e., it does not include any interface with the surrounding space, e.g., the surrounding medium or body fluids, according to the above definition. The matrix should be understood as a solid sphere having a radius and therefore a volume that is usually smaller than the volume of the particle. The volume of the matrix is ​​usually greater than 50% of the total volume, preferably greater than 60%, 70%, 80%, 90%, and most preferably greater than 95%, e.g., greater than 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95%.

[0080] As used herein. The term "aggregation" or "phase separation" refers to particle formation by a salting-out mechanism, which can be considered as liquid-liquid phase separation in particular. The "one-phase state" is the initial state exhibited by a solution of monomeric, intrinsically unfolded protein molecules. Changing constraints, such as ionic strength, for example by the addition of kosmotropic ions, alters the free energy of the system, resulting in phase separation into a protein-rich phase and a solvent-rich phase. This phase-separated state is energetically favorable, and the protein concentration in the "protein phase" increases up to a critical level. When the critical concentration for nucleation is reached, several structured nuclei are simultaneously formed in the protein-rich phase. The nuclei interact with additional monomers, thereby changing their structure and starting to grow into spheres. When the protein concentration in the protein-rich phase is below the solubility equilibrium, the growth of the spheres stops. Thus, the sphere size does not increase any more. Phase separation therefore means that the protein-rich phase and the solvent-rich phase separate. Without wishing to be bound by theory, the sphere size generally depends on the protein concentration and the mixing conditions. However, there are various other methods in the art for causing protein aggregation.

[0081] The process of microsphere construction is typically monitored by light scattering after aggregation has occurred. In particular, the colloidal stability of the resulting particles can be analyzed by measuring the intensity of scattered light at a certain wavelength. Also, the average particle size and particle size distribution can be determined by laser diffraction, also called static light scattering (SLS).

[0082] The resulting particles may also be analyzed using methods such as scanning electron microscopy (SEM) and Fourier transform infrared spectroscopy (FTIR). Further description of these methods can be found in the description and examples below.

[0083] After phase separation, the resulting particles can be isolated by routine methods such as centrifugation, filtration, or sedimentation. The prepared particles can then be washed and / or stored, for example, in a dried or lyophilized form.

[0084] The term "net charge on the surface of a particle" refers to the sum of charges, such as positive and negative charges, on the surface of a particle. For example, if a particle contains more negative charges than positive charges on its surface, the net charge on the surface of the particle is negative. If a particle contains more positive charges than negative charges on its surface, the net charge on the surface of the particle is positive. If a particle contains an equal number of positive and negative charges on its surface, the net charge on the surface of the particle is neutral, in particular electrically neutral. Thus, the net charge on the surface of a particle according to the present invention can be negative, positive, or neutral. Preferably, the particle of the present invention has a net negative surface charge.

[0085] The term "average diameter" refers to the average diameter of a particle and can be calculated by dividing the sum of the diameters of each particle by the total number of particles. The term "diameter" is usually used to refer to the maximum length of a line segment that passes through the center of a sphere and connects two points on the outer surface of the sphere, but is also used herein to refer to the maximum length of a line segment that passes through the center of a particle having a substantially spherical or other shape and connects two points on the outer surface of the particle.

[0086] As used herein, the term "protease (also named peptidase or proteinase)" refers to any enzyme that performs proteolysis, i.e., initiates a protein catabolic reaction by hydrolysis of the peptide bonds that link the amino acids together in a polypeptide chain. Proteases have evolved multiple times, and different classes of proteases may carry out the same reaction by completely different catalytic mechanisms. Proteases can be found in animals, plants, bacteria, archaea, and viruses.

[0087] As used herein, the term "cathepsin (CTS)" refers to a protease (an enzyme that breaks down proteins) found in all animals, as well as other organisms. There are different family members that are differentiated by their structure, catalytic mechanism, and which proteins they cleave. The majority of members are active at the low pH found in lysosomes. Thus, the activity of this family is exclusively within those organelles. The cathepsin can be cathepsin A, cathepsin B, cathepsin C, cathepsin D, cathepsin E, cathepsin F, cathepsin G, cathepsin H, cathepsin K, cathepsin L1, cathepsin L2, cathepsin O, cathepsin S, cathepsin W, or cathepsin Z. Preferably, the cathepsin is cathepsin S or B. More preferably, the cathepsin is cathepsin S.

[0088] In one embodiment, the polypeptide of the invention or used in the invention comprises a protease cleavable linker, such as a cathepsin S cleavable linker or a cathepsin B cleavable linker. Preferably, the cathepsin S cleavable linker has a sequence according to SEQ ID NO: 1 or is a variant thereof, or has a sequence according to SEQ ID NO: 2 or is a variant thereof, or the cathepsin B cleavable linker has a sequence according to SEQ ID NO: 2 or is a variant thereof. In this respect, it should be noted that cathepsin S can cleave its own cleavage site (contained within SEQ ID NO: 1) and also the cleavage site normally cleaved by cathepsin B (contained within SEQ ID NO: 2). The sequence according to SEQ ID NO: 1 (GPMGLPG) comprises the cleavage site PMGLP (SEQ ID NO: 20), and the sequence according to SEQ ID NO: 2 (GAVGFLGIG) comprises the cleavage site GFLG (SEQ ID NO: 21). Instead of the cleavage site GFLG (SEQ ID NO: 21), the dipeptide Val-Cit or the tetrapeptides ALAL (SEQ ID NO: 22) or GGGF (SEQ ID NO: 23) can be used as cathepsin B cleavage site. The cleavage sites Val-Cit, ALAL (SEQ ID NO: 22) or GGGF (SEQ ID NO: 23) can be effective in combination with C16 CathBseq-SIINFEKL (SEQ ID NO: 15) particles. In this case, the cleavage site GFLG (SEQ ID NO: 21) in the sequence according to SEQ ID NO: 15 is replaced by Val-Cit, ALAL (SEQ ID NO: 22) or GGGF (SEQ ID NO: 23). It is also possible that the cathepsin-cleavable linker contained in the polypeptide of the invention consists of the cleavage site Val-Cit or the cleavage site according to SEQ ID NO: 20 to 23.

[0089] EMBODIMENTS OF THE PRESENT DISCLOSURE The inventors of the present patent application have surprisingly found that antigens that are part of articles, e.g., particles, that contain silk polypeptides, are preferentially taken up by animal cells, e.g., human cells. In this context, the inventors of the present patent application have been surprised that articles, e.g., particles, that are mainly composed of silk, function as auxiliary substances that stabilize antigens and allow them to be transported. The articles, e.g., particles, can be decomposed without leaving a trace in an organism (e.g., the human body). The articles, e.g., particles, are non-toxic, in particular non-cytotoxic, and non-immunogenic.

[0090] Thus, in a first aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: (i) a silk polypeptide, and (ii) (polypeptide) antigen The present invention relates to a polypeptide comprising:

[0091] Polypeptide can be a molecule composed of at least two components, which can be translated as a single-chain polypeptide from the same mRNA molecule, or can be produced by separate translation of at least two components and then coupling, for example by chemical reaction.In the first case, silk polypeptide is fused / attached to antigen.In the second case, silk polypeptide is linked / coupled to antigen.Preferably, polypeptide is a single-chain polypeptide, which can also be named hybrid polypeptide or fusion polypeptide.

[0092] In one preferred embodiment, the polypeptide further comprises an enzyme-cleavable linker. The linker can be any linker that can be cleaved by enzyme. When an enzyme-cleavable linker is present, the antigen is connected to the silk polypeptide via the linker, or the linker is located between the silk polypeptide and the antigen. When the polypeptide is produced as a single-chain polypeptide (also named hybrid polypeptide or fusion polypeptide), the antigen is attached / fused to the silk polypeptide via an enzyme-cleavable linker. When the polypeptide is produced by separate translation of at least two components and subsequent coupling, for example by chemical reaction, the antigen is linked / coupled to the silk polypeptide via an enzyme-cleavable linker. It is particularly preferred that the enzyme-cleavable linker can be cleaved intracellularly, for example by an enzyme in a host cell.

[0093] Preferably, the enzyme-cleavable linker is a protease-cleavable linker. The linker may be any linker that is cleavable by a protease.

[0094] More preferably, the protease cleavable linker is a cathepsin cleavable linker. The cathepsin can be cathepsin A, cathepsin B, cathepsin C, cathepsin D, cathepsin E, cathepsin F, cathepsin G, cathepsin H, cathepsin K, cathepsin L1, cathepsin L2, cathepsin O, cathepsin S, cathepsin W, or cathepsin Z. The cathepsin cleavable linker can be cathepsin A, cathepsin B, cathepsin C, cathepsin D, cathepsin E, cathepsin F, cathepsin G, cathepsin H, cathepsin K, cathepsin L1, cathepsin L2, cathepsin O, cathepsin S, cathepsin W, or cathepsin Z cleavable linker.

[0095] Even more preferably, the cathepsin cleavable linker is a cathepsin B cleavable linker or a cathepsin S cleavable linker. Cathepsin S cleavable linkers are particularly preferred.

[0096] Cathepsin B is a member of the peptidase C1 family. It is a lysosomal cysteine ​​protease with both endopeptidase and exopeptidase activities. It plays a role in protein turnover. It is also known as amyloid precursor protein secretase and is involved in the proteolytic processing of amyloid precursor protein (APP). Cathepsin B is ubiquitously expressed in almost every tissue. In contrast, cathepsin S is expressed only in certain tissues. In particular, cathepsin S is expressed by antigen-presenting cells, including macrophages, B lymphocytes, dendritic cells, and microglia. In addition, cathepsin S is expressed by some epithelial cells. Cathepsin S is also a member of the peptidase C1 family. It is a lysosomal cysteine ​​protease. It plays a key role in the degradation of antigenic proteins and their further processing by the MHC class II pathway. Cathepsin S can cleave its own cleavage site (see, e.g., SEQ ID NO: 1) as well as the cleavage site normally cleaved by cathepsin B (see, e.g., SEQ ID NO: 2). In this regard, it should be noted that cathepsin S cleaves the cleavage site normally cleaved by cathepsin B to a lesser extent.

[0097] Most preferably, (i) the cathepsin S cleavable linker has a sequence according to SEQ ID NO: 1 or is a variant thereof, or has a sequence according to SEQ ID NO: 2 or is a variant thereof, or (ii) The cathepsin B cleavable linker has a sequence according to SEQ ID NO:2 or is a variant thereof.

[0098] The inventors of the present patent application have found that cathepsin S can cleave cathepsin S cleavable linkers, such as cathepsin S cleavable linkers having a sequence according to SEQ ID NO:1, as well as cathepsin B cleavable linkers, such as cathepsin B cleavable linkers having a sequence according to SEQ ID NO:2.

[0099] A SEQ ID NO:1 or SEQ ID NO:2 variant differs from the reference sequence from which it is derived by up to one, two, three, or four amino acid changes in amino acid sequence (i.e., substitutions, additions, insertions, deletions, N-terminal truncations, and / or C-terminal truncations). Such variants may be characterized as alternative or additional by a certain degree of sequence identity with the reference module from which it is derived. Thus, SEQ ID NO:1 variants or SEQ ID NO:2 variants have at least 60%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or even 99.9% sequence identity with the respective reference sequences.Preferably, the sequence identity is over the entire length of the respective sequences.

[0100] A fragment (or deletion variant) of SEQ ID NO:1 or SEQ ID NO:2 preferably has a deletion of up to 1, 2, 3, or 4 amino acids at its N-terminus and / or its C-terminus. The deletion may also be internal.

[0101] In addition, a variant or fragment of SEQ ID NO:1 or SEQ ID NO:2 is considered within the context of the present invention as a variant or fragment of SEQ ID NO:1 or SEQ ID NO:2 only if the modification with respect to the amino acid sequence on which the variant or fragment is based does not negatively affect the ability of a cathepsin, e.g., cathepsin S or B, to cleave this sequence. Whether cathepsin S or B is still capable of cleaving a SEQ ID NO:1 variant or a SEQ ID NO:2 variant can be readily assessed by one skilled in the art, for example, by performing an enzyme assay on a test substrate comprising the modified sequence.

[0102] The silk polypeptide may be a spider silk polypeptide, for example a major ampullate silk polypeptide, a minor ampullate silk polypeptide, or a flagellate silk polypeptide, such as a traction silk polypeptide, of orb spiders (e.g., Araneidae or Araneoids), an insect silk polypeptide, a mussel byssus silk polypeptide, or a mixture thereof. Orb spiders may be selected from the group consisting of Araneus diadematus, Nephila clavipes, and Latrodectus hesperus. The insect silk polypeptide may be of the order Lepidoptera, in particular of the family Bombycidae, such as Bombyx mori. The insect silk polypeptide may also be of the order Hymenoptera, in particular of the superfamily Apoidea, such as Anthophila. Preferably, the silk polypeptide is a spider silk polypeptide.

[0103] It is preferred that the silk polypeptide is a polypeptide having an amino acid sequence that comprises or consists of multiple copies of at least 50%, 60%, 65%, 70%, 75%, 80%, 85% or 90% of the repeating unit. It is more preferred that the silk polypeptide is a polypeptide having an amino acid sequence that comprises or consists of multiple copies of at least 95% of the repeating unit. The repeating units can be identical or different. It is particularly preferred that the silk polypeptide comprises at least two identical repeating units. For example, silk polypeptides may have between 2 and 100 repeating units, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 108, 109, 109, 110, 111, 112, 113, 114, 11 , 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 repeating units.

[0104] It is further (alternatively or additionally) preferred that the silk polypeptide consists of between 40 and 3000 amino acids. It is more preferred that the silk polypeptide consists of between 40 and 1500 amino acids. It is even more preferred that the silk polypeptide consists of between 200 and 1200 amino acids. It is most preferred that the silk polypeptide consists of between 250 and 600 amino acids.

[0105] It is also preferred (alternatively or additionally) that the silk polypeptide is a recombinant silk polypeptide.

[0106] As mentioned above, it is particularly preferred that the silk polypeptide comprises at least two identical repeating units. In one embodiment, the repeating unit is module C (SEQ ID NO: 3) or a variant thereof, module C Cys (SEQ ID NO: 4) and module C カッパ (SEQ ID NO: 18). Module C Cys (SEQ ID NO: 4) is a variant of module C (SEQ ID NO: 3). In this module, the amino acid S (Ser) at position 25 is replaced by the amino acid C (Cys). Module C カッパ (SEQ ID NO: 18) is also a variant of module C (SEQ ID NO: 3), in which the amino acid E (Glu) at position 20 is replaced by the amino acid K (Lys).

[0107] A module C variant differs in amino acid sequence from the reference module C from which it is derived by up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid changes (i.e., substitutions, additions, insertions, deletions, N-terminal truncations, and / or C-terminal truncations). Such module variants may be characterized as alternative or additional by a certain degree of sequence identity with the reference module from which it is derived. Thus, module C variants have at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or even 99.9% sequence identity with the respective reference module C. Preferably, the sequence identity is over a contiguous stretch of at least 5, 10, 15, 18, 20, 24, 27, 28, 30, 34, 35 or more amino acids of each reference module C, preferably over the entire length.

[0108] It is particularly preferred that the sequence identity is at least 80% over the entire length of each reference module C, at least 85% over the entire length, at least 90% over the entire length, at least 95% over the entire length, at least 98% over the entire length, or at least 99% over the entire length. It is particularly preferred that the sequence identity is at least 80% over a contiguous stretch of at least 5, 10, 15, 18, 20, 24, 28, or 30 amino acids of each module C, at least 85% over a contiguous stretch of at least 5, 10, 15, 18, 20, 24, 28, or 30 amino acids, and at least 90% over a contiguous stretch of at least 5, 10, 15, 18, 20, 24, 28, or 30 amino acids. and at least 95% for a contiguous stretch of at least 5, 10, 15, 18, 20, 24, 28, or 30 amino acids, at least 98% for a contiguous stretch of at least 5, 10, 15, 18, 20, 24, 28, or 30 amino acids, or at least 99% for a contiguous stretch of at least 5, 10, 15, 18, 20, 24, 28, or 30 amino acids, being even more particularly preferred.

[0109] A fragment (or deletion) variant of module C preferably has a deletion of up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids at its N-terminus and / or its C-terminus. The deletion may also be internal.

[0110] In addition, a module C variant or fragment is considered as a module C variant or fragment within the context of the present invention only if the modification with respect to the amino acid sequence on which the variant or fragment is based does not negatively affect the ability of the silk polypeptide to internalize an antigen into a target cell. Whether a silk polypeptide comprising a module C variant or fragment is still capable of internalizing an antigen into a target cell can be easily assessed by one skilled in the art, for example, by culturing target cells, e.g., BMDCs, with fluorescently labeled, e.g., FITC-labeled, spider silk particles comprising the antigen, and performing flow cytometry analysis (see Example 11 in the Experimental Section).

[0111] C Cys or C カッパ Variants are also encompassed by the present invention. Cys or C カッパ Regarding the variants, the same explanations / definitions apply as given for module C variants (see above).

[0112] In contrast to the use of module C (SEQ ID NO: 3) or a variant thereof, C カッパ The use of a positively charged protein such as (SEQ ID NO: 18) results in a positive surface charge on the article at neutral pH. The positive surface charge may enhance uptake into cells.

[0113] It is also particularly preferred that the silk polypeptide comprises at least one non-repetitive (NR) unit. The non-repetitive (NR) unit may be included at the N-terminus and / or C-terminus. In one embodiment, the NR unit is selected from the group consisting of NR3 (SEQ ID NO: 7) or a variant thereof, NR4 (SEQ ID NO: 8) or a variant thereof, NR5 (SEQ ID NO: 9) or a variant thereof, and NR6 (SEQ ID NO: 10) or a variant thereof. The NR3 (SEQ ID NO: 7) unit is based on the amino acid sequence of ADF-3 of the spider Araneus diadematus, and the NR4 (SEQ ID NO: 8) unit is based on the amino acid sequence of ADF-4 of the spider Araneus diadematus (WO 2006 / 008163). In addition, the NR5 (SEQ ID NO: 9) unit and the NR6 (SEQ ID NO: 10) unit are derived from the spider Latrodectus hesperus.

[0114] Regarding variants of NR3, NR4, NR5 or NR6 units, the same explanations / definitions apply as given for module C variants (see above).

[0115] A variant or fragment of an NR3, NR4, NR5, or NR6 unit is considered as a variant or fragment of an NR3, NR4, NR5, or NR6 unit within the context of the present invention only if the modification with respect to the amino acid sequence on which the variant or fragment is based does not negatively affect the ability of the silk polypeptide to internalize an antigen into a target cell. A person skilled in the art can easily assess whether a silk polypeptide comprising a variant or fragment of an NR3, NR4, NR5, or NR6 unit is still capable of internalizing an antigen into a target cell, for example, by culturing a target cell, for example, a BMDC, with a fluorescently labeled, for example, FITC-labeled, spider silk particle containing the antigen, and performing a flow cytometry analysis (see Example 11 in the Experimental Section).

[0116] It is further particularly preferred that the silk polypeptide comprises at least one tag (sequence). The tag can be comprised at the N-terminus and / or C-terminus. The tag is preferably non-repetitive. It is suitable for purifying and / or detecting the silk polypeptide. The tag can be a His tag or a T7 tag. Preferably, the T7 tag has a sequence according to SEQ ID NO:5 or a sequence according to SEQ ID NO:6.

[0117] In one preferred embodiment, the silk polypeptide is (C) m , (C Cys ) m , (C カッパ ) m、 (C) m C Cys , C Cys (C) m , (C) m C Cys (C) m , (C) m NR z , N.R. z (C) m , and N.R. z (C) m NR z wherein m is an integer from 8 to 96, i.e., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 108, 109, 109, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 1 z is an integer from 1 to 3, i.e., 1, 2, or 3, and NR represents a non-repeating unit.

[0118] In one more preferred embodiment, the silk polypeptide is 16 , C 32 , C 48、 Cカッパ 8. C カッパ 16 , C カッパ 32 , C カッパ 48 , C8C Cys , C 16 C Cys , C 32 C Cys , and C 48 C Cys is selected from the group consisting of:

[0119] Preferably, the antigen is a disease-associated antigen. More preferably, the antigen, in particular the disease-associated antigen, is selected from the group consisting of a viral antigen, a microbial antigen such as a bacterial or fungal antigen, an animal parasitic antigen, and a tumor antigen.

[0120] As an exemplary antigen, the inventors of the present patent application have identified an epitope of chicken ovalbumin (OVA) having the amino acid sequence SIINFEKL (SEQ ID NO: 11). 257~264 ) was used. The chicken ovalbumin epitope with the amino acid sequence SIINFEKL (SEQ ID NO: 11) was chosen because it is the best characterized and generally applied system for demonstrating / monitoring the effect of peptide-epitopes on immune responses. This chicken ovalbumin epitope system with the amino acid sequence SIINFEKL (SEQ ID NO: 11) is a state-of-the-art tool and resembles a universally valid example for the presentation of a plethora of antigens to the immune system. For the experiments presented herein, the inventors of the present patent application used a C 16 The inventors of this patent application recombinantly produced different polypeptides comprising a silk polypeptide and an antigen, or a silk polypeptide, an enzyme-cleavable linker, and an antigen. Spider silk polypeptide C 16 and chicken ovalbumin epitopes (OVA 257~264 The polypeptide comprising spider silk polypeptide C has a sequence according to SEQ ID NO: 13. 16, a cathepsin-cleavable linker, and an epitope of chicken ovalbumin (OVA) 257~264 The polypeptide comprising spider silk polypeptide C has a sequence according to SEQ ID NO: 14. 16 , a cathepsin B cleavable linker, and an epitope of chicken ovalbumin (OVA) 257~264 ) has a sequence according to SEQ ID NO:15.

[0121] In a second aspect, the present invention relates to a nucleic acid molecule encoding a polypeptide of the first aspect.

[0122] It is preferred that the nucleic acid molecule is contained in a vector. The vector may be any vector known to those skilled in the art. For example, the vector may be a plasmid vector, a viral vector such as an adenovirus vector or a baculovirus vector, a cosmid vector, or a phage vector such as a lambda phage vector. The vector includes expression vectors in addition to cloning vectors. Expression vectors generally contain a desired coding sequence and a suitable DNA sequence for regulating the expression of the operably linked coding sequence in a specific host organism (e.g., bacteria, yeast, plants, insects, or mammals) or in an in vitro expression system. The expression control sequence may be (i) a sequence that regulates expression, such as a promoter, a TATA box, an enhancer, (ii) a sequence that regulates post-transcriptional events, such as polyadenylation, and (iii) a sequence that regulates the translation of a nucleic acid sequence. Cloning vectors are generally used to manipulate and amplify a particular desired DNA fragment and may lack functional sequences required for the expression of the desired DNA fragment. The vectors mentioned above are preferably recombinant vectors.

[0123] The cells may be transformed, transfected, or infected with the nucleic acid molecule or a vector containing the nucleic acid molecule. The cells may be used to express the nucleic acid molecule or to amplify the nucleic acid molecule or a vector containing the nucleic acid molecule. The cells may be prokaryotic or eukaryotic. The prokaryotic cells may be E. coli cells or Bacillus subtilis cells. The eukaryotic cells may be mammalian, plant, yeast, or insect cells. The mammalian cells may be CHO, COS, HeLa, 293T, HEH, or BHK cells. The yeast cell may be a Saccharomyces cerevisiae cell, a Schizosaccharomyces pombe cell, a Pichia pastoris cell, a Candida albicans cell, or a Hansenula polymorpha cell. The insect cell may be a Lepidoptera insect cell. The plant cell may be a tobacco cell, a potato cell, a corn cell, a pea cell, or a tomato cell. The above mentioned cells may also be called host cells. They are preferably recombinant cells.

[0124] In a third aspect, the present invention provides a method for producing a polypeptide comprising the steps of: (a) expressing a nucleic acid molecule of the second aspect in a cell, thereby producing said polypeptide in said cell. The present invention relates to a method comprising the steps of:

[0125] The cell may also be referred to as a host cell. The cell may be a prokaryotic or eukaryotic cell. The prokaryotic cell may be an E. coli cell or a Bacillus subtilis cell. The eukaryotic cell may be a mammalian cell, a plant cell, a yeast cell, or an insect cell. The mammalian cell may be a CHO, COS, HeLa, 293T, HEH, or BHK cell. The yeast cell may be a Saccharomyces cerevisiae cell, a Schizosaccharomyces pombe cell, a Pichia pastoris cell, a Candida albicans cell, or a Hansenula polymorpha cell. The insect cell may be a Lepidoptera insect cell. The plant cell may be a tobacco cell, a potato cell, a corn cell, a pea cell, or a tomato cell. The above mentioned cells are preferably recombinant cells.

[0126] The nucleic acid molecule may be found within the cell (i) by itself, freely distributed, (ii) incorporated into a vector, or (iii) integrated into the cellular genome or mitochondrial DNA. Preferably, the vector, e.g., a plasmid or viral vector, is an expression vector.

[0127] The cell may be transformed, transfected or infected with the nucleic acid molecule or a vector containing the nucleic acid molecule.

[0128] Preferably, the method comprises: (b) isolating the polypeptide from the cells. Further includes:

[0129] Isolation of polypeptide from cells can be achieved by separating the polypeptide from the cells by centrifugation, sedimentation, and / or filtration, for example, by centrifugation and filtration, by sedimentation and filtration, by sedimentation and centrifugation, or by centrifugation, sedimentation, and filtration. Depending on the polypeptide to be harvested, the parameters for centrifugation, sedimentation, or filtration can be different. Those skilled in the art can easily adapt the appropriate separation parameters, for example, the acceleration force / G force and / or time for using centrifugation for separation, the filter size for using filtration for separation, and / or the sedimentation time for using sedimentation for separation, to harvest the polypeptide produced by the cells.

[0130] After step (b), further purification of the isolated polypeptide may be required. Said purification can be achieved by chromatography, preferably column chromatography, more preferably size exclusion chromatography, hydrophobic interaction chromatography, ion exchange chromatography, affinity chromatography or high pressure liquid chromatography, electrophoresis, preferably gel electrophoresis, or ultracentrifugation. A preferred isolation method for producing polypeptide is described in WO2011 / 120690 A2.

[0131] In one preferred embodiment, the purified polypeptide is endotoxin-free. Endotoxin removal is achieved by filtration, steam sterilization (e.g., in an autoclave), or a combination of both, i.e., filtration and steam sterilization (e.g., in an autoclave).

[0132] In a fourth aspect, the present invention relates to an article comprising a polypeptide of the first aspect, which article may also be referred to as an antigen carrier or antigen carrier vehicle.

[0133] The article may be selected from the group consisting of particles, capsules, fibres, films, granules, gels, fabrics made of fibres, rods or bundles thereof. Preferably, the rods comprise or consist of fibres. Preferably, the fabric is a woven or non-woven fabric. It is preferred that said article is non-cytotoxic and non-immunogenic. It is further (alternatively or additionally) preferred that said article is sterilizable.

[0134] Preferably, the article is a particle. It is preferred that the particle is non-cytotoxic and non-immunogenic. It is further (alternatively or additionally) preferred that the article is sterilizable. The particle is preferably a nanoparticle, since cellular uptake is a major aspect of its pathway of action and is therefore desirable. In one embodiment, the particles have an average diameter in the range of 50 nm to 1000 nm, e.g., 100 nm to 900 nm, 200 nm to 800 nm, 200 nm to 700 nm, 300 nm to 600 nm, 300 nm to 500 nm, or 300 nm to 400 nm. The range of 250 nm to 520 nm is particularly preferred. In a further embodiment, the particles have an average diameter of at least 50 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 150 nm, at least 200 nm, at least 250 nm, at least 300 nm, at least 400 nm, at least 500 nm, at least 600 nm, at least 700 nm, at least 800 nm, at least 900 nm, and / or the particles have an average diameter of 1000 nm or less, 900 nm or less, 800 nm or less, 700 nm or less, 600 nm or less, 520 nm or less, 500 nm or less, 400 nm or less, 300 nm or less, 250 nm or less, 200 nm or less, 150 nm or less, 100 nm or less, 90 nm or less, 80 nm or less, 70 nm or less, 60 nm or less. In one preferred embodiment, the particles have an average diameter in the range of (i) from 50 nm to 400 nm, preferably from 50 nm to 200 nm, or (ii) from 200 nm to 1000 nm, preferably from 200 nm to 800 nm, more preferably from 250 nm to 520 nm or from 300 nm to 600 nm.

[0135] In a fifth aspect, the present invention provides a method for making an article, comprising the steps of: (a) providing an aqueous solution comprising a polypeptide of the first aspect; and (b) forming an article out of / from the solution provided in (a). The present invention relates to a method comprising the steps of:

[0136] The article may also be referred to as an antigen carrier or an antigen carrier vehicle.

[0137] Because the silk polypeptide and the antigen are part of the same polypeptide, no additional loading step is required after article formation.

[0138] The article, which is primarily composed of silk, acts as an adjuvant to stabilize the antigen and make it transportable, and can degrade without leaving a trace within a living organism (e.g., the human body).

[0139] The above article-forming process does not require organic solvents, the avoidance of which has the advantage that organic solvent-sensitive antigens retain their characteristic properties.

[0140] Preferably, the concentration of the polypeptide in the aqueous solution is between 0.1% and 30% by weight / volume, more preferably between 1% and 20% by weight / volume, even more preferably between 1% and 20% by weight / volume, and most preferably between 2-8% by weight / volume or 4-6% by weight / volume. Thus, for example, the concentration of the polypeptide in the aqueous solution is 0.1, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 15.0, 18.0, 20.0, 25.0, or 30.0% by weight / volume.

[0141] The aqueous solution may be a buffered aqueous solution or water (H2O), such as industrial H2O or deionized H2O. The buffered aqueous solution may be, for example, Tris / HCl. Preferably, the pH of the buffered aqueous solution is between pH 5.0 and pH 9.0, more preferably between pH 6.0 and pH 8.0, even more preferably between pH 6.7 and pH 7.2, such as Tris / HCl, pH 7.0, pH 7.5, or pH 8.0. Preferably, the buffered aqueous solution is between 10 mM and 100 mM Tris / HCl, more preferably between 10 and 50 mM Tris / HCl, most preferably between 10 and 20 mM Tris / HCl, such as a solution of 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mM Tris / HCl.

[0142] The article may be selected from the group consisting of particles, capsules, fibres, films, granules, gels, fabrics made of fibres, rods or bundles thereof. Preferably, the rods comprise or consist of fibres. Preferably, the fabric is a woven or non-woven fabric. It is preferred that the article is non-cytotoxic and non-immunogenic. It is further (alternatively or additionally) preferred that the article is sterilizable.

[0143] In one embodiment, the article is a particle. It is preferred that the particle is non-cytotoxic and non-immunogenic. It is further (alternatively or additionally) preferred that the particle can be sterilized. Generally, starting from an aqueous solution, aggregation of polypeptides can be induced under certain conditions to form particles. When the article is a particle, step (b) comprises inducing aggregation of polypeptides. Thus, in one preferred embodiment, the method is for making particles, (a) providing an aqueous solution comprising a polypeptide of the first aspect; and (b) forming particles out of / from the solution provided in (a), the formation including causing aggregation of the polypeptide. The aggregation can be induced by pH shift, ion exchange, shear stress, addition of alcohol, addition of salt, removal of water, temperature change, and combinations thereof. The alcohol can be ethanol or methanol. The salt is preferably a lyotropic salt. The lyotropic salt can be selected from the group consisting of ammonium sulfate, sodium phosphate, and potassium phosphate. In one further (alternatively or additionally) preferred embodiment, the method further comprises: (c) isolating the particles by phase separation After phase separation, the produced particles can be further separated by routine methods such as centrifugation, sedimentation, and / or filtration. The particle size can be optimized by adjusting one or more of the following parameters: silk polypeptide and / or salt concentration, temperature during preparation, mixing intensity, and / or organic or aqueous solvent used for protein precipitation. Alternatively or additionally, the particle size can be optimized by adjusting the geometry of the mixing device, such as an agitator, static mixer, etc. The prepared particles can then be washed. The particles can also be stored, for example, in a dried or lyophilized form. The process can be carried out under sterile conditions. The particles are preferably nanoparticles, since cellular uptake is a major aspect of their pathway of action and is therefore desirable.

[0144] In an alternative embodiment, the article is a fiber. In this case, the aqueous solution may also be referred to as a spinning solution. It is preferred that the fiber is non-cytotoxic and non-immunogenic. It is further (alternatively or additionally) preferred that the fiber can be sterilized. If the article is a fiber, step (b) comprises drawing the fiber from the aqueous solution / spinning solution or extruding and drawing the fiber from the aqueous solution / spinning solution. Thus, in one preferred embodiment, the method is for making a fiber, (a) providing an aqueous solution comprising a polypeptide of the first aspect; and (b) forming a fiber out of / from the solution provided in (a), said forming comprising pulling the fiber out of the aqueous solution / spinning solution or extruding and drawing the fiber out of the aqueous solution / spinning solution. Spinning methods, such as wet spinning or electrospinning, are known to those skilled in the art. For example, an aqueous solution / spinning solution is extruded through a spinneret to form a fiber. The resulting fiber can be further drawn or stretched. Whenever both crystalline and non-crystalline configurations of molecules are present in the fiber, drawing or stretching provides sufficient shear stress to orient the molecules so that they are more parallel to the fiber wall, increasing the tensile strength and toughness of the fiber. The fibers can be used to make fabrics, such as woven or non-woven fabrics. Those skilled in the art are familiar with techniques that allow for, for example, weaving processes to make fabrics. Thus, in an alternative embodiment, the article can be a fabric made of fibers. The fiber can also be part of a rod. Preferably, the rod includes or consists of a fiber. A bundle of rods can also be included in the present invention.

[0145] In an alternative embodiment, the article is a film. In this case, the aqueous solution may be referred to as a casting solution. It is preferred that the film is non-cytotoxic and non-immunogenic. It is further (alternatively or additionally) preferred that the film is sterilizable. When the article is a film, step (b) comprises casting an aqueous solution / casting solution comprising the polypeptide onto a support. Thus, in one preferred embodiment, the method is for making a film, (a) providing an aqueous solution comprising a polypeptide of the first aspect; and (b) forming a film out of / from the solution provided in (a), said forming comprising casting an aqueous / casting solution comprising the polypeptide onto a support. In one further (alternatively or additionally) preferred embodiment, the method further comprises: (c) Separating / removing the film from the support Includes.

[0146] In one alternative embodiment, the article is a capsule. It is preferred that the capsule is non-cytotoxic and non-immunogenic. It is further (alternatively or additionally) preferred that the capsule is sterilizable.

[0147] When the article is a capsule, step (b) comprises producing an at least two phase emulsion, the emulsion containing the solution provided in (a) as a first phase and at least one further phase that is substantially immiscible with said first phase, and forming a polymer network of the polypeptide at the interface of said at least two phases. Thus, in one preferred embodiment, the method is for making a capsule, (a) providing an aqueous solution comprising a polypeptide of the first aspect; and (b) forming capsules out of / from the solution provided in (a), said forming comprising the steps of producing an emulsion of at least two phases, said emulsion containing the solution provided in (a) as a first phase and at least one further phase that is substantially immiscible with said first phase, and forming a polymeric network of polypeptides at the interface of said at least two phases. In one further (alternatively or additionally) preferred embodiment, the method further comprises: (c) separating the protein polymer network (capsules) from the emulsion. This may be done by centrifugation, sedimentation, and / or filtration. A preferred method for making capsules from polypeptides is described in WO 2007 / 014755 A1.

[0148] The article may also be a granule or a gel. A preferred method for making a gel from a polypeptide is described in WO 2007 / 014755 A1.

[0149] In a sixth aspect, the present invention relates to a pharmaceutical composition comprising the article of the fourth aspect.

[0150] The article may also be referred to as an antigen carrier or an antigen carrier vehicle.

[0151] The article may be selected from the group consisting of particles, capsules, fibers, and films. It is preferred that said article is non-cytotoxic and non-immunogenic. It is further (alternatively or additionally) preferred that said article is sterilizable.

[0152] The inventors of this patent application have surprisingly found that after systemic administration of the article, accumulation of the article occurs in local lymph nodes and / or in antigen-presenting cells, particularly dendritic cells and / or macrophages.In addition, the article forms a depot under the skin.The antigen carried by the article induces an immune response in said cells.

[0153] The pharmaceutical composition is useful for treating, preventing, or reducing the severity of a disease or disorder. It can be administered locally or systemically. It is preferred that the pharmaceutical composition is formulated for local or systemic administration. In particular, local administration is by parenteral administration, such as intravenous administration, subcutaneous administration, intradermal administration, intramuscular administration, and systemic administration is by intraarterial administration. Preferably, the composition is administered subcutaneously, intradermally, or intramuscularly.

[0154] The composition further comprises one or more pharma- ceutically acceptable carriers, diluents, and / or excipients. An adjuvant may additionally be present.

[0155] The inventors of this patent application have surprisingly found that the use of adjuvants in pharmaceutical compositions comprising antigens that are part of articles, such as particles, that comprise silk polypeptides is no longer required.The efficacy of the antigens contained in compositions without adjuvants is better than, or at least as good as, the same antigens contained in compositions with adjuvants.Omission of adjuvants has the positive effect that side effects and vaccine incompatibility can be reduced and even avoided in some cases.Therefore, it is alternatively preferred that said compositions do not further comprise adjuvants.

[0156] In a seventh aspect, the present invention relates to an article of the fourth aspect or a pharmaceutical composition of the sixth aspect for use as a medicament. The medicament may be a vaccine, for example for inducing an immune response, such as for immunization or vaccination, or an anti-cancer drug, or for immunotherapy.

[0157] In an eighth aspect, the present invention relates to the article of the fourth aspect or the pharmaceutical composition of the sixth aspect for inducing an immune response.

[0158] Preferably, the immune response against cancer is induced.Cancer can be, for example, carcinoma, lymphoma, blastoma, sarcoma, or leukemia.More specifically, cancer can be, for example, bone cancer, blood cancer, lung cancer, liver cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal region cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, uterine cancer, genital and reproductive organs carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue sarcoma, bladder cancer, kidney cancer, renal cell carcinoma, renal pelvis carcinoma, central nervous system (CNS) neoplasm, neuroectodermal cancer, spinal axis tumor, glioma, meningioma, or pituitary adenoma.

[0159] It is further (alternatively or additionally) preferred that an immune response against infectious disease or autoimmune disease is induced. The infectious disease can be, for example, a viral disease, a bacterial disease, or a parasitic disease. More specifically, the infectious disease can be, for example, hepatitis, sexually transmitted disease (e.g., chlamydia or gonorrhea), tuberculosis, HIV / acquired immune deficiency syndrome (AIDS), diphtheria, hepatitis B, hepatitis C, cholera, severe acute respiratory syndrome (SARS), avian influenza, or influenza. The autoimmune disease can be, for example, Hashimoto's thyroiditis, Graves' disease, lupus, multiple sclerosis, rheumatoid arthritis, hemolytic anemia, autoimmune thyroiditis, systemic lupus erythematosus, celiac disease, Crohn's disease, colitis, diabetes, scleroderma, or psoriasis.

[0160] The induction of an immune response may occur upon immunization or vaccination of the subject / patient to be treated.

[0161] In a ninth aspect, the present invention relates to the article of the fourth aspect or the pharmaceutical composition of the sixth aspect for use in the preventive and / or therapeutic treatment of a disease.

[0162] Preferably, the disease is cancer.Cancer can be, for example, carcinoma, lymphoma, blastoma, sarcoma, or leukemia.More specifically, cancer can be, for example, bone cancer, blood cancer, lung cancer, liver cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal region cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, uterine cancer, genital and reproductive organs carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue sarcoma, bladder cancer, kidney cancer, renal cell carcinoma, renal pelvis carcinoma, central nervous system (CNS) neoplasm, neuroectodermal cancer, spinal axis tumor, glioma, meningioma, or pituitary adenoma.

[0163] It is furthermore preferred (alternatively or additionally) that the disease is an infectious disease or an autoimmune disease. The infectious disease can be, for example, a viral disease, a bacterial disease, or a parasitic disease. More specifically, the infectious disease can be, for example, hepatitis, sexually transmitted diseases (e.g., chlamydia or gonorrhea), tuberculosis, HIV / acquired immune deficiency syndrome (AIDS), diphtheria, hepatitis B, hepatitis C, cholera, severe acute respiratory syndrome (SARS), avian influenza, or influenza. The autoimmune disease can be, for example, Hashimoto's thyroiditis, Graves' disease, lupus, multiple sclerosis, rheumatoid arthritis, hemolytic anemia, autoimmune thyroiditis, systemic lupus erythematosus, celiac disease, Crohn's disease, colitis, diabetes, scleroderma, or psoriasis. It is furthermore preferred that the disease is a respiratory disease.

[0164] Antigens as described herein are preferably applied directly to the target area. Direct application of antigens to the target area allows for higher local active pharmaceutical ingredient (API) concentrations, while at the same time minimizing the adverse side effects of systemic application. The use of aerosolized articles (particles, microparticles, or capsules) may improve API deposition in the lower respiratory tract. Pulmonary antigen delivery or pulmonary vaccination allows for the induction of immune responses systemically, since a large number of immune cells are located in the mucous membranes of the mouth, nose, or lung tissues. Pulmonary administration of articles (particles, microparticles, or capsules) is an attractive delivery approach for pulmonary vaccination, since peptides are protected by the particles and released once the particles are taken up by antigen-presenting cells. Since there is always a risk of losing the loaded antigen during the aerosolization process, the article of the fourth aspect, the pharmaceutical composition of the sixth aspect, or the article or pharmaceutical composition used according to the seventh to ninth aspects are promising alternatives. Due to the incorporation of the active pharmaceutical moiety into the amino acid sequence of the antigen carrier molecule, the risk of antigen loss during nebulization is very low.

[0165] In a further aspect, the invention relates to the article of the fourth aspect or the pharmaceutical composition of the sixth aspect for stimulating, priming and / or expanding T cells in a subject.

[0166] In a tenth aspect, the present invention relates to a method for delivering an antigen to a cell comprising administering to a subject an article of the fourth aspect or a pharmaceutical composition of the sixth aspect.

[0167] In a preferred embodiment, the administering step includes internalizing the article into the cell and releasing the antigen from the article. It is preferred that the antigen is released from the article by an enzyme, which cleaves the enzyme-cleavable linker (intracellularly, inside the cell), thereby delivering the antigen to the cell. Preferably, the enzyme-cleavable linker is a protease-cleavable linker, more preferably a cathepsin-cleavable linker, even more preferably a cathepsin S or B cleavable linker, most preferably (i) a cathepsin S cleavable linker having a sequence according to SEQ ID NO: 1 or a variant thereof, or a cathepsin S cleavable linker having a sequence according to SEQ ID NO: 2 or a variant thereof, or (ii) a cathepsin B cleavable linker having a sequence according to SEQ ID NO: 2. The enzyme is preferably a protease, more preferably a cathepsin, even more preferably a cathepsin S or B.

[0168] Preferably, the cell is an antigen-presenting cell. More preferably, the antigen-presenting cell is a dendritic cell and / or a macrophage.

[0169] The subject may be healthy and the antigen is delivered for immunization or vaccination. The subject may also be diseased (i.e., a patient), for example, suffering from cancer, and the antigen is delivered to cure the disease.

[0170] In an eleventh aspect, the present invention relates to a method for inducing an immune response in a subject comprising administering to the subject an article of the fourth aspect or a pharmaceutical composition of the sixth aspect.

[0171] Preferably, the immune response against cancer is induced.Cancer can be, for example, carcinoma, lymphoma, blastoma, sarcoma, or leukemia.More specifically, cancer can be, for example, bone cancer, blood cancer, lung cancer, liver cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal region cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, uterine cancer, genital and reproductive organs carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue sarcoma, bladder cancer, kidney cancer, renal cell carcinoma, renal pelvis carcinoma, central nervous system (CNS) neoplasm, neuroectodermal cancer, spinal axis tumor, glioma, meningioma, or pituitary adenoma.

[0172] It is further (alternatively or additionally) preferred that an immune response against infectious disease or autoimmune disease is induced. The infectious disease can be, for example, a viral disease, a bacterial disease, or a parasitic disease. More specifically, the infectious disease can be, for example, hepatitis, sexually transmitted disease (e.g., chlamydia or gonorrhea), tuberculosis, HIV / acquired immune deficiency syndrome (AIDS), diphtheria, hepatitis B, hepatitis C, cholera, severe acute respiratory syndrome (SARS), avian influenza, or influenza. The autoimmune disease can be, for example, Hashimoto's thyroiditis, Graves' disease, lupus, multiple sclerosis, rheumatoid arthritis, hemolytic anemia, autoimmune thyroiditis, systemic lupus erythematosus, celiac disease, Crohn's disease, colitis, diabetes, scleroderma, or psoriasis.

[0173] The induction of an immune response may occur upon immunization or vaccination of the subject / patient to be treated.

[0174] In a twelfth aspect, the present invention relates to the prophylactic and / or therapeutic treatment of a disease in a subject comprising administering to the subject an article of the fourth aspect or a pharmaceutical composition of the sixth aspect.

[0175] Preferably, the disease is cancer.Cancer can be, for example, carcinoma, lymphoma, blastoma, sarcoma, or leukemia.More specifically, cancer can be, for example, bone cancer, blood cancer, lung cancer, liver cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal region cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, uterine cancer, genital and reproductive organs carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue sarcoma, bladder cancer, kidney cancer, renal cell carcinoma, renal pelvis carcinoma, central nervous system (CNS) neoplasm, neuroectodermal cancer, spinal axis tumor, glioma, meningioma, or pituitary adenoma.

[0176] It is further (alternatively or additionally) preferred that the disease is an infectious disease or an autoimmune disease.The infectious disease can be, for example, a viral disease, a bacterial disease, or a parasitic disease.More specifically, the infectious disease can be, for example, hepatitis, sexually transmitted disease (e.g., chlamydia or gonorrhea), tuberculosis, HIV / acquired immune deficiency syndrome (AIDS), diphtheria, hepatitis B, hepatitis C, cholera, severe acute respiratory syndrome (SARS), avian influenza, or influenza.The autoimmune disease can be, for example, Hashimoto's thyroiditis, Graves' disease, lupus, multiple sclerosis, rheumatoid arthritis, hemolytic anemia, autoimmune thyroiditis, systemic lupus erythematosus, celiac disease, Crohn's disease, colitis, diabetes, scleroderma, or psoriasis.

[0177] In a thirteenth aspect, the present invention relates to a method for stimulating, priming and / or expanding T cells in a subject comprising administering to the subject an article of the fourth aspect or a pharmaceutical composition of the sixth aspect.

[0178] The present invention is summarized as follows: 1. (i) a silk polypeptide, and (ii) Antigen A polypeptide comprising: 2. The polypeptide according to item 1, wherein the polypeptide further comprises an enzyme-cleavable linker. 3. The polypeptide according to item 2, wherein the antigen is linked to the silk polypeptide via the enzyme-cleavable linker. 4. The polypeptide according to item 2 or 3, wherein the enzyme-cleavable linker is a protease-cleavable linker. 5. The polypeptide according to item 4, wherein the protease-cleavable linker is a cathepsin-cleavable linker. 6. The polypeptide according to item 5, wherein the cathepsin-cleavable linker is a cathepsin S-cleavable linker or a cathepsin B-cleavable linker. 7. (i) the cathepsin S cleavable linker has a sequence according to SEQ ID NO: 1 or a variant thereof, or has a sequence according to SEQ ID NO: 2 or a variant thereof; or (ii) The polypeptide according to item 6, wherein the cathepsin B cleavable linker has a sequence according to SEQ ID NO: 2 or a variant thereof. 8. The polypeptide of any one of items 1 to 7, wherein the silk polypeptide is a recombinant silk polypeptide. 9. The polypeptide according to any one of the preceding claims, wherein the silk polypeptide comprises at least two identical repeating units. 10. The repeating unit comprises a module C having a sequence according to SEQ ID NO: 3 or a variant thereof, a module C having a sequence according to SEQ ID NO: 4 Cys and module C having the sequence according to SEQ ID NO: 18 カッパ 10. The polypeptide according to item 9, independently selected from the group consisting of: 11. The polypeptide according to any one of items 1 to 10, wherein the silk polypeptide comprises at least one non-repetitive (NR) unit and / or tag. 12. The polypeptide according to any one of the preceding claims, wherein the antigen is selected from the group consisting of a viral antigen, a microbial antigen, preferably a bacterial or fungal antigen, an animal parasitic antigen, and a tumor antigen. 13. A nucleic acid molecule encoding a polypeptide according to any one of items 1 to 12. 14. A method for producing a polypeptide, comprising: (a) expressing in a cell the nucleic acid molecule of item 13, thereby producing the polypeptide in the cell. 15. The polypeptide according to item 14, further comprising the step of (b) isolating the polypeptide from the cell. 16. An article comprising a polypeptide according to any one of items 1 to 12. 17. The article according to item 16, wherein the article is selected from the group consisting of particles, capsules, fibers, films, granules, gels, fabrics made of fibers, rods or bundles thereof. 18. The article of item 17, wherein the particles have an average diameter in the range of 50 nm to 1000 nm. 19. The article of any one of items 17 or 18, wherein the particles have a net negative surface charge. 20. The article of any one of items 17 to 19, wherein the particles are non-cytotoxic and non-immunogenic. 21. The article of any one of items 17 to 20, wherein the particles are sterilizable. 22. A method for making an article, comprising: (a) providing an aqueous solution comprising a polypeptide according to any one of items 1 to 12; (b) forming an article out of / from the solution provided in (a). 23. The method according to item 22, wherein the concentration of the polypeptide in the aqueous solution is between 0.1% w / v and 30% w / v, preferably between 1% w / v and 20% w / v. 24. The polypeptide according to item 22 or 23, wherein the article is a particle and step (b) comprises causing aggregation of the polypeptide. 25. The method according to item 24, wherein the aggregation is induced by pH shift, ion exchange, shear stress, addition of alcohol, addition of salt, preferably a lyotropic salt, removal of water, temperature change and combinations thereof. 26. (i) the alcohol is ethanol or methanol, or (ii) The method of claim 25, wherein the lyotropic salt is selected from the group consisting of ammonium sulfate, sodium phosphate, and potassium phosphate. 27. The method of any one of items 24 to 26, further comprising the step of (c) isolating the particles by phase separation. 28. A pharmaceutical composition comprising an article according to any one of items 16 to 21. 29. The pharmaceutical composition according to item 28, further comprising one or more pharma- ceutically acceptable carriers, diluents, and / or excipients. 30. The pharmaceutical composition according to item 28 or 29, further comprising an adjuvant. 31. The pharmaceutical composition according to item 28 or 29, which does not further comprise an adjuvant. 32. An article according to any one of items 16 to 21 or a pharmaceutical composition according to any one of items 28 to 31 for use as a medicament. 33. An article according to any one of items 16 to 21 or a pharmaceutical composition according to any one of items 28 to 31 for inducing an immune response. 34. An article according to any one of items 16 to 21 or a pharmaceutical composition according to any one of items 28 to 31 for use in the preventive and / or therapeutic treatment of a disease. 35. A method for delivering an antigen to a cell, comprising administering to a subject an article according to any one of items 16 to 21 or a pharmaceutical composition according to any one of items 28 to 31. 36. The method of claim 35, wherein the cell is an antigen-presenting cell. 37. The method according to item 36, wherein the antigen-presenting cells are dendritic cells and / or macrophages. 38. A method for inducing an immune response in a subject, comprising administering to the subject an article according to any one of items 16 to 21 or a pharmaceutical composition according to any one of items 28 to 31. 39. A method for the preventive and / or therapeutic treatment of a disease in a subject, comprising administering to the subject an article according to any one of items 16 to 21 or a pharmaceutical composition according to any one of items 28 to 31. 40. A method for stimulating, priming and / or expanding T cells in a subject, comprising administering to the subject an article according to any one of items 16 to 21 or a pharmaceutical composition according to any one of items 28 to 31.

[0179] The sequence listing contains the following sequences: SEQ ID NO:1 Cathepsin S cleavable linker SEQ ID NO:2 Cathepsin S and B cleavable linker Sequence number 3 Module C Sequence number 4 Module C Cys SEQ ID NO: 5 T7-tag SEQ ID NO:6 T7-tag SEQ ID NO: 7 NR3 unit SEQ ID NO:8 NR4 unit SEQ ID NO: 9 NR5 unit SEQ ID NO:10 NR6 unit SEQ ID NO: 11 Epitope of chicken ovalbumin (OVA 257~264 ), SIINFEKL SEQ ID NO:12 C16 SEQ ID NO:13 C16-SIINFEKL SEQ ID NO:14 C16-CathS-SIINFEKL SEQ ID NO: 15 C16-CathB-SIINFEKL SEQ ID NO: 16 Cathepsin B cleavable linker and epitope of chicken ovalbumin (OVA 257~264 ) the IGSIINFEKLG sequence cleaved from the hybrid polypeptide SEQ ID NO: 17 Cathepsin S cleavable linker and epitope of chicken ovalbumin (OVA 257~264 ) the LPGSIINFEKLG sequence cleaved from the hybrid polypeptide SEQ ID NO:18 Module Cカッパ

[0180] It should be noted that with respect to SEQ ID NO:12 to SEQ ID NO:15, the C-terminal G (Gly) may or may not be present.

[0181] Various modifications and variations of the present invention will be apparent to those of skill in the art without departing from the scope of the present invention. Although the present invention has been described in connection with certain preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be covered by the present invention.

[0182] Working Example The examples given below are for illustrative purposes only and are not intended to limit the above invention in any way. The terms "SIIN" and "SIINFEKL", as well as the terms "NP" and "spider silk particle", the terms "SIIN" and "SIINFEKL", the terms "C16-CathB-SIINFEKL", "C16-CathB-SIIN", "eADF4(C16) CathB" and "SSP25 - eADF4(C16-CathB-CD8)", and the terms "C16-CathS-SIINFEKL", "C16-CathS-SIIN", "eADF4(C16)CathS" and "SSP26 - eADF4(C16-CathS-CD8)" are used interchangeably herein. SIINFEKL (SEQ ID NO: 11) binds to an epitope of chicken ovalbumin (OVA). 257~264 ) This antigen stimulates an immune response through interaction with MHC I and the CD8 T cell receptor.

[0183] Example 1: Production of silk polypeptide antigen particles The polypeptides SSP25-eADF4(C16-CathS-CD8) (1), SSP26-eADF4(C16-CathB-CD8) (2), C16-SIIN (3), and C16 (4) were synthesized by gene synthesis at Geneart (Regensburg). (1) C16-CathS-SIINFEKL, respectively, SSP26-eADF4 (C16-CathS-CD8) (SEQ ID NO: 14) (C16)GPMGLPG SIINFEKL A hybrid polypeptide comprising C16, a cathepsin S protease cleavage site, and SIINFEKL (SEQ ID NO:11). (2) C16-CathB-SIINFEKL, respectively, SSP25-eADF4 (C16-CathB-CD8) (SEQ ID NO: 15) (C16)GAVGFLGIG SIINFEKL A hybrid polypeptide comprising C16, a cathepsin B protease cleavage site, and SIINFEKL (SEQ ID NO:11). (3) C16-SIINFEKL (SEQ ID NO: 13) (C16)GGSGSIINFEKL A hybrid polypeptide comprising C16 and SIINFEKL (SEQ ID NO:11). (4) C16 (SEQ ID NO: 12) C16 A hybrid polypeptide that does not contain the antigen (SIINFEKL (SEQ ID NO: 11)).

[0184] Polypeptides encoding SSP25-eADF4 (C16-CathB-CD8), SSP26-eADF4 (C16-CathS-CD8), C16-SIINFEKL, and C16 were produced and purified as described in WO 2006 / 008163 A2.

[0185] Example 2: Sterilization by autoclaving In the first step, approximately 150 mg of protein (C16-CathB-SIINFEKL, C16-CathS-SIINFEKL, C16-SIINFEKL, and C16) was weighed into glass vials (DIN 10R). The C16 protein was then suspended in 7.5 ml HPW (high purity water). The vials were closed with rubber stoppers and covered with aluminum caps. Steam sterilization was performed at 121° C. for 15 min in a GTA 50 autoclave (Fritz Gossner, Hamburg, Germany). After cooling, the C16 protein suspension was centrifuged at 10,000 rpm (SIGMA 4K15, Sigma Laborzentrifugen, Osterode am Harz, Germany) for 30 min and the supernatant was discarded. The centrifuged C16 protein was dissolved in 6 M guanidine thiocyanate solution and dialyzed against endotoxin-free 10 mM TRIS / HCl solution, pH 8.0, for 24 hours.

[0186] After dialysis, the protein concentration of C16-CathB-SIINFEKL was 3.91 mg / ml, that of C16-CathS-SIINFEKL was 3.56 mg / ml, that of C16-SIINFEKL was 3.81 mg / ml, and that of C16 was 3.88 mg / ml. The protein concentration of all solutions was adjusted to 1 mg / ml. Endotoxin values ​​of the solutions were <0.200 EU / mg. Sterilization of spider silk particles did not have a detrimental effect on particle size, secondary structure, and thermal stability. No changes in particle size or secondary structure, and no functional changes were observed after sterilization by autoclaving. Retention of functionality after sterilization is advantageous given the prior art systems.

[0187] Example 3: Particle Preparation After endotoxin removal, protein solutions (C16-CathB-SIINFEKL, C16-CathS-SIINFEKL, C16-SIINFEKL, and C16) were adjusted to 1 mg / ml in endotoxin-free 10 mM TRIS / HCl buffer, pH 8.0, for particle preparation. Particle preparation was performed by micromixing using a high-pressure syringe pump system. The syringe pump cylinders were depyrogenated with 70% (v / v) ethanol for 48 hours. The cylinders were then washed three times with HPW to remove any organic solvents. After depyrogenation, both cylinders of the syringe pump system (Model 100 DX and Series D pump controller, Teledyne Isco, Lincoln, USA) were filled with 80° pre-formulated C16 solution and pre-formulated endotoxin-free 2 M potassium phosphate buffer, pH 8.0 or 4 M ammonium sulfate. The solution was pumped at a high flow rate of 50 ml / min into a T-shaped mixing element (0.5 mm inner diameter, P-727 PEEK tee, Upchurch Scientific, Oak Harbor, USA) leading to an outlet tubing (0.5 mm inner diameter, 1532 PEEK tubing, Upchurch Scientific, Oak Harbor, USA) for suspension collection. The C16 particle suspension was then centrifuged at 14,000 rpm (SIGMA 4K15, Sigma Laborzentrifugen, Osterode am Harz, Germany) and washed three times with HPW. A final 2 min sonication (Sonopuls HD 3200, Bandelin electronic, Berlin, Germany) step completed the particle preparation procedure. The particle concentration in mg / ml was determined gravimetrically after drying the particles overnight under reduced pressure (13 mbar).

[0188] The particle concentration of C16-CathB-SIINFEKL was 32.75 mg / ml, the protein concentration of C16-CathS-SIINFEKL was 34.72 mg / ml, the protein concentration of C16-SIINFEKL was 30.06 mg / ml, and the protein concentration of C16 was 32.52 mg / ml.

[0189] Example 4: Optimization of C16 particle size The micromixed particle preparation process was analyzed for further reduction of the final particle size. Several parameters were selected to be changed compared to the preparation process described above. The concentration of the C16 solution used for the particle preparation was adjusted to 0.5-1.0 mg / ml. The 2 M potassium phosphate solution used so far for particle precipitation was supplemented by 2 M, 3 M, and 4 M ammonium sulfate solutions. The flow rate of the salt solution was kept at 50 ml / min, while the flow rate of the protein solution was set at 25-50 ml / min. For this study, native C16 protein was used. All other parameters were kept as above, and the final particle size was analyzed after particle preparation with the modified syringe pump settings described here. The resulting particles have an average diameter ranging from 250 nm to 520 nm.

[0190] Example 5: In vitro release of SIINFEKL (SEQ ID NO: 11) from hybrid C16 particles (in vitro) The release of the antigen sequence SIINFEKL (SEQ ID NO: 11) from the hybrid polypeptides SSP25-eADF4 (C16-CathB-CD8) and SSP26-eADF4 (C16-CathS-CD8) was tested by the addition of cathepsin enzymes. Since the hybrid polypeptides contain cleavable linker sequences for cathepsin S and cathepsin B enzymes, these two cathepsins were also used in the in vitro release studies.

[0191] C16 hybrid polypeptide particles were suspended in 50 mM sodium acetate buffer, pH 5.5, containing 1 mM EDTA and 2 mM DTT to a final concentration of 2 mg / ml for incubation with cathepsin S enzyme. Cathepsin S was diluted in the same buffer to a final concentration of 0.9 mU / ml. For cathepsin B enzyme, a slight pH modification of the buffer was achieved.

[0192] C16 hybrid polypeptide particles were suspended in 50 mM sodium acetate buffer, pH 5.0, containing 1 mM EDTA and 2 mM DTT to a final concentration of 2 mg / ml for incubation with cathepsin B enzyme. Cathepsin B was diluted in the same buffer to a final concentration of 0.1 U / ml. Incubation of particles with the enzyme was performed at 10 rpm and 37°C on a waving platform shaker (Heidolph Polymax 1040, Heidolph Instruments GmbH, Schwabach, Germany). Samples (supernatants) were withdrawn after 1, 6, 24, 48, 72, and 96 hours and used for analysis by RP-HPLC.

[0193] The cleaved SIINFEKL (SEQ ID NO: 11) peptide fragments were analyzed by RP-HPLC. The supernatant of each sample was removed from the particles by centrifugation (2 times 30 min at 12,000 rpm). The pellet was discarded and 180 μl of the supernatant was filled into an HPLC glass insert and analyzed by RP-HPLC (detection by UV-Vis at 220 nm). A volume of 50 μl of the corresponding supernatant was separated at 30° C. on a reversed-phase YMC-Triart C18 column (YMC Europe GmbH, Dinslaken, Germany) using a Waters 2695 separation module (Waters Corporation, Milford, MA, USA). A gradient with two mobile phases was applied, using water + 0.1% [m / m] TFA (mobile phase A) and 100% acetonitrile + 0.1% [m / m] TFA (mobile phase B). Each run started with 95% mobile phase A for 2 min, followed by a linear increase from 5% to 100% mobile phase B over 28 min. A 5 min wash step with 100% mobile phase B was used to wash residual peptides / proteins from the column. The separation run was stopped with a 5 min equilibration of the column in 95% mobile phase A. Detection was performed at a wavelength of 220 nm to detect the SIINFEKL (SEQ ID NO: 11) peptide in a Waters UV-Vis detector 2487 (Waters Corporation, Milford, MA, USA). The amount of released SIINFEKL (SEQ ID NO: 11) peptide was analyzed using a standard curve. In particular, cleavage of the SIINFEKL (SEQ ID NO: 11) peptide of the hybrid polypeptide with a cathepsin S cleavable linker yielded the sequence IGSIINFEKLG (SEQ ID NO: 16). In addition, cleaving the SIINFEKL (SEQ ID NO: 11) peptide of the hybrid polypeptide with a cathepsin S cleavable linker yielded the sequence LPGSIINFEKLG (SEQ ID NO: 17). SIINFEKL (SEQ ID NO: 11) is included in IGSIINFEKLG (SEQ ID NO: 16) as well as LPGSIINFEKLG (SEQ ID NO: 17).These two peptides were used for the standard curve at concentrations of 10 μg / mL, 20 μg / mL, 30 μg / mL, 50 μg / ml, and 100 μg / ml dissolved in 50% DMSO / 50% water. The area of ​​each peptide in the chromatogram was integrated and used for the calculation of the calibration curve after injection and analysis. Data analysis was performed with Chromeleon® 6.80 software (Dionex GmbH, Germering, Germany).

[0194] FIG. 7A shows the total release in percent of cleaved SIINFEKL (SEQ ID NO: 11) peptide for the hybrid polypeptides SSP25-eADF4 (C16-CathB-CD8) and SSP26-eADF4 (C16-CathS-CD8) as a function of time (1, 6, 24, 48, 72, and 96 hours).

[0195] Cathepsin S enzyme shows better cleavage of the SIINFEKL (SEQ ID NO: 11) peptide from both hybrid polypeptide particles. Cathepsin S also cleaves the SIINFEKL (SEQ ID NO: 11) peptide from particles designed for release by cathepsin B, but more slowly and to a lesser extent. This was unexpected, since the linker (PMGLP, SEQ ID NO: 20) designated for cleavage by the cathepsin S enzyme was not designated for cleavage of the cathepsin B linker sequence (GFLG, SEQ ID NO: 21).

[0196] In contrast to cathepsin B, cathepsin S is only expressed in certain tissues. Cathepsin S plays a key role in the degradation of antigenic proteins and their further processing through the major histocompatibility complex class II pathway. Cathepsin S linker particles were selected for in vivo mouse studies.

[0197] Figure 7A shows incubation of hybrid protein particles with cathepsin S enzyme, while Figure 7B shows incubation of hybrid protein particles with cathepsin B enzyme. Enzymatic cleavage of SIINFEKL (SEQ ID NO: 11) peptide from SSP hybrid protein particles was successful in vitro, which provides the basis for further in vitro and in vivo studies.

[0198] Example 6: Spider silk hybrid particles do not induce BMDC cytotoxicity Preparation of bone marrow derived dendritic cells (BMDCs) BMDCs were generated from primary bone marrow cells obtained by flushing the tibias and femurs of C57BL / 6Rj mice with cold PBS. Red blood cell lysis was performed with BD Pharm Lyse (BD Biosciences, USA) for 1 min. Cells were then resuspended in complete BMDC medium consisting of RPMI 1640 (Biowest, France) supplemented with 10% FCS (Biological Industries, Israel), 1% L-glutamine, 50 U / mL penicillin, 50 U / mL streptomycin, 50 μM 2-mercaptoethanol, and 0.5 mM sodium pyruvate (all from PAA Laboratories, Austria), supplemented with 40 ng / ml GM-CSF (PeproTech, USA). After 6 days of differentiation, loosely attached cells were harvested. The percentage of CD11c+CD11b+ cells routinely exceeded 70%.

[0199] Exposure to spider silk particles BMDCs (5 × 10 per well) 4Cells) were seeded in flat-bottom 96-well plates (Corning, New York, USA) in the presence of C16 particles (untreated), C16 hybrid particles (containing SIIN polypeptide (SIIN), SEQ ID NO: 13), C16 hybrid particles with cathepsin B cleavage site (C16-CathBseq-SIIN, SEQ ID NO: 15), and C16 hybrid particles with cathepsin S cleavage site (C16-CathSseq-SIIN, SEQ ID NO: 14) at 505 μg particles / mL (=10 μg SIINFEKL (SEQ ID NO: 11) / mL) diluted in 100 μL complete medium per well (which is 10-fold the concentration used in other in vitro experiments). TLR7 agonist R848 (Invitrogen, USA) was used as an immunostimulant. After 24 h of incubation, cells were harvested for flow cytometry analysis, while supernatants were saved for cytokine quantification. BMDC viability was assessed by flow cytometry and MTT assay.

[0200] Fluorescent labeling Labeling of C16-, C16-SIIN-, C16-CathBseq-SIIN-, and C16-CathSseq-SIIN- polypeptides with fluorescein isothiocyanate (FITC) was performed using the terminal amine group of C16 based on the method published by Spiess et al. (Spiess et al., 2010). SIIN polypeptide was obtained from GenScript Inc., Piscataway Township, NJ, USA. For the preparation of particles used in in vivo studies, C16 protein powder dried protein suspended in HPW was autoclaved as described previously. After steam sterilization, the autoclaved C16 powder was dissolved in 6 M guanidine thiocyanate solution, but this time dialyzed against endotoxin-free 20 mM HEPES solution, pH 8.0, for 24 h at 2–8 °C. After dialysis, centrifugation, and filtration, the solution was adjusted to a concentration of 2.0 mg / ml in endotoxin-free 20 mM HEPES solution, pH 8.0, for coupling in solution. A 20-fold molar excess of FITC (dissolved in DMSO) was slowly added to the C16 solution. After addition of the entire amount of dissolved FITC, the solution was incubated in the dark at room temperature for 3 hours. After incubation, the FITC-coupled C16 protein solution was first filtered through a 0.2 μm PES filter (VWR International, Radnor, USA) and then through a pre-flushed Mustang® E filter. The filtered FITC-coupled C16 protein solution was adjusted to a protein concentration of 1 mg / ml for particle preparation by a syringe pump system at 80° C. All other parameters were identical to the particle preparation process described previously. Fluorescent labeling of particles used only for in vitro studies was performed in the final particles. C16 particles were suspended at a concentration of 2.5 mg / ml in endotoxin-free 20 mM HEPES solution, pH 8.0. A 20-fold molar excess of FITC (dissolved in DMSO) was added dropwise to the particle suspension. After 72 hours of incubation in the dark, the particles were centrifuged and washed three times with HPW. A final 2 minutes of additional sonication completed the FITC labeling process of the final C16 polypeptide particles.

[0201] Dynamic Light Scattering (DLS) Particle size and size distribution of submicron particles were measured in triplicate by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). Particle size is shown as the Z-average value and particle size distribution is expressed by the polydispersity index (PDI). Immediately before each measurement, samples were diluted in HPW to a final concentration of 0.01 mg / ml. All measurements were performed at 25°C.

[0202] cytotoxicity Cytotoxicity was assessed by flow cytometry using propidium iodide (PI) and Annexin V staining as well as by assay. For flow cytometry analysis, BMDCs were incubated with APC-Annexin V (both from Biolegend, USA) diluted 1:100 in Annexin V buffer for 30 min at room temperature. 0.2 μL PI (Sigma-Aldrich, USA) diluted 1:2 in PBS was automatically added by the MACS quantitative analyzer (Miltenyi Biotec, Germany) immediately before analysis. All flow cytometry data were analyzed using FlowJo version 10.0.8r1. Staurosporine (1 nM) (Sigma-Aldrich, USA) was used as a positive control (not shown). For MTT assay, the Vybrant MTT cell proliferation assay kit (Molecular Probes, USA) was used according to the manufacturer's protocol. For this assay, complete BMDC medium without phenol red (Biowest, France) was used.

[0203] BMDC cell phenotype After washing with FACS buffer consisting of PBS (Eurobio, France) supplemented with 2 mM EDTA (Calbiochem, Germany) and 0.5% BSA (PAA laboratories, Austria), BMDC cells were incubated with anti-mouse CD16 / 32 (Biolegend, USA) to block Fc receptors. After 10 min of incubation at 4°C, antibodies against activation markers or their respective isotype controls were added: PB-CD80, PE-CD86, APC-MHCI, and FITC-CD11b (all from Biolegend, USA). Dead cells were excluded using Zombie Violet dye (Biolegend, USA). After 30 min of incubation at 4°C, cells were washed and resuspended in FACS buffer before acquisition.

[0204] Figure 1A shows dot plots from flow cytometry with propidium iodide (PI) and annexin V. No difference in cell viability could be detected between cells without C16 particles (untreated), SIIN polypeptide (SIIN), C16 particles (C16), C16 hybrid particles with a cathepsin B cleavage site (C16-CathBseq-SIIN), and C16 hybrid particles with a cathepsin S cleavage site (C16-CathSseq-SIIN).

[0205] FIG. 1B shows a schematic diagram of live healthy cells, dead cells, and apoptotic cells.

[0206] Figure 1C shows the percentage of live cells with SIIN, C16-CathBseq-SIIN, and C16-CathSseq-SIIN compared to untreated cells and cells with C16 particles. No difference in cell viability could be detected between cells without C16 particles (untreated), SIIN polypeptide (SIIN), C16 particles (C16), C16 hybrid particles with cathepsin B cleavage site (C16-CathBseq-SIIN), and C16 hybrid particles with cathepsin S cleavage site (C16-CathSseq-SIIN).

[0207] FIG. 1D shows the optical density (OD) at 570 nm, which correlates with formazan production, from the MTT assay. There is no difference in optical density between the spider silk particles, as well as the spider silk hybrid particles, compared to the control (untreated). This indicates that the spider silk particles, as well as the spider silk hybrid particles, did not induce BDMC cytotoxicity.

[0208] Example 7: Spider silk particles do not induce BMDC immunological activation in vitro Preparation of bone marrow derived dendritic cells (BMDCs) BMDCs were generated from primary bone marrow cells obtained by flushing the tibias and femurs of C57BL / 6Rj mice with cold PBS. Red blood cell lysis was performed with BD Pharm Lyse (BD Biosciences, USA) for 1 min. Cells were then resuspended in complete BMDC medium consisting of RPMI 1640 (Biowest, France) supplemented with 10% FCS (Biological Industries, Israel), 1% L-glutamine, 50 U / mL penicillin, 50 U / mL streptomycin, 50 μM 2-mercaptoethanol, and 0.5 mM sodium pyruvate (all from PAA Laboratories, Austria), supplemented with 40 ng / ml GM-CSF (PeproTech, USA). After 6 days of differentiation, loosely attached cells were harvested. The percentage of CD11c+CD11b+ cells routinely exceeded 70%.

[0209] BMDC(5×10 4 cells / well) were cultured with spider silk particles at 50 μg particles (spider silk particles) / mL.

[0210] BMDC phenotype After washing with FACS buffer consisting of PBS (Eurobio, France) supplemented with 2 mM EDTA (Calbiochem, Germany) and 0.5% BSA (PAA laboratories, Austria), cells were incubated with anti-mouse CD16 / 32 (Biolegend, USA) to block Fc receptors. After 10 min of incubation at 4°C, antibodies against immune activation markers or their respective isotype controls were added: PB-CD80, PE-CD86, APC-MHCI, and FITC-CD11b (all from Biolegend, USA). Dead cells were excluded using Zombie Violet dye (Biolegend, USA). After 30 min of incubation at 4°C, cells were washed and resuspended in FACS buffer before acquisition.

[0211] After 24 h of incubation, BMDCs were analyzed by flow cytometry, while supernatants were collected for cytokine quantification.

[0212] Analysis of cytokine production by ELISA ELISA Max Deluxe Set for Mouse IL-6 (Biolegend, USA) was used according to the manufacturer's protocol. Protein concentration was measured by Infinite 200 PRO plate reader (TECAN, Switzerland) and absorbance at 570 nm was subtracted from absorbance at 450 nm. Concentration was calculated according to a standard curve performed in duplicate.

[0213] Figure 2A shows the median fluorescence intensity (MFI) of BMDC surface activation markers MHC I and MHC II for BMDC cells cultured with SIIN, C16-SIIN, CathBseq-SIIN, and C16-CathSseq-SIIN compared to untreated samples. R848 (R8), a TLR7 agonist, was used as a positive control. No significant increase in immune activation markers MHC I and MHC II could be detected. This indicates that spider silk particles, as well as spider silk hybrid particles, are not immunogenic.

[0214] Figure 2B shows cytokine quantification by ELISA. TLR7 agonist, R848 (R8), was used as a positive control, demonstrating that spider silk particles, as well as spider silk hybrid particles, have no intrinsic immunostimulatory activity.

[0215] Example 8: Spider silk particles are efficiently taken up by antigen-presenting cells According to Example 6, BMDCs (5 × 10 4 Cells / well) were cultured with 50 μg particles / mL of FITC-labeled spider silk particles (C16-SIIN, C16-CathBseq-SIIN, and C16-CathSseq-SIIN). After 24 h of incubation, BMDCs were isolated for flow cytometry analysis.

[0216] The uptake of spider silk particles by BMDCs was evaluated by flow cytometry and confocal microscopy. For flow cytometry, dead cells were excluded using Zombie Violet dye (Biolegend, USA). After Fc receptor blocking, the following antibodies were added: APC-CD11b, APC-Cy7-CD11c (both from Biolegend, USA). The percentage of FITC+ positive cells in the CD11b+CD11c+ population was then determined. For confocal microscopy, BMDCs were incubated with Blue DND-22 Lysotracker (Molecular Probes, USA) for 1 h and incubated with FITC-positive particles for an additional 4 h before imaging with confocal microscopy (Zeiss, Germany). The percentage of FITC-positive cells within the BMDC (CD11c+) population was determined. SIIN polypeptide served as a negative control.

[0217] FIG. 3A shows the uptake of C16 particles without SIIN (C16), C16 hybrid particles C16-SIIN, C16 hybrid particles with cathepsin B cleavage site (C16-CathBseq-SIIN), and C16 hybrid particles with cathepsin S cleavage site (C16-CathSseq-SIIN). Untreated cells (untreated) and SIIN polypeptide (SIIN) served as controls. Higher than 90% particle uptake could be obtained for the hybrid particles. No significant difference in uptake could be detected between the hybrid polypeptides C16-CathBseq-SIIN and C16-CathSseq-SIIN and the particles without antigen (C16). This indicates that the hybrid particles are taken up similarly to the particles without antigen (C16).

[0218] Splenocytes were isolated from C57BL / 6JRj mice, passed through a 20 μm cell strainer, and red blood cell lysis was performed. Dead cells were excluded using Violet Zombie dye (Biolegend, USA). Freshly isolated splenocytes (5 × 10 4Cells / well) were cultured with FITC-labeled spider silk particles for 6 hours. After Fc receptor blocking, the following antibodies were added: PerCP-CD3, APC-CD11b, APC-Cy7-CD11c (all from Biolegend, USA). After 6 hours of incubation, cells were analyzed by flow cytometry. Figure 3B shows the percentage of FITC-positive cells determined in defined immune cell populations: T cells (CD3+), dendritic cells (CD11c+CD11b+), and monocytes / macrophages (CD11c-CD11b+) compared to untreated cells. Hybrid particles C16-CathSseq-SIIN were efficiently taken up by dendritic cells and subsequently by monocytes / macrophages and T cells.

[0219] Example 9: Cathepsin S sequence is more effective in inducing SIINFEKL (SEQ ID NO: 11)-dependent in vitro T cell proliferation In vitro T cell proliferation BMDC(5×10 4 BMDCs were cultured with spider silk particles at 50 μg particles / mL. R848 (0.25 μg / mL) was used as an adjuvant to induce BMDC activation. After 24 h of incubation, CFSE-labeled CD3+CD8+ OT-I cells (10 5 After 3 days of co-culture, the detection of CFSE-positive CD3+CD8+ cells was analyzed by flow cytometry.

[0220] After 24 h of incubation, CD8+ T cells were negatively selected from OT-I splenocytes using a CD8+ T cell isolation kit (Miltenyi Biotech, Germany). These cells were then stained with CFSE (Molecular Probes, USA) according to the manufacturer's protocol and were then cultured with BMDC cultures (10 5After 3 days, cells were stained for flow cytometry analysis. After Fc blocking, the following antibodies were added: PB-CD3, APC-Cy7-CD8 (all from Biolegend, USA). Proliferation was assessed by CFSE in the CD3+CD8+ cell population. DIM It was determined by the percentage of cells.

[0221] Figure 4A shows the percentage of proliferative CD8+ T cells in the T cell population (CD3+CD8+). The percentage of proliferative CD8 T cells exposed to BMDC cells with C16 CathSseq-SIINFEKL particles and C16 CathBseq-SIINFEKL particles was significantly higher than that of untreated controls. The percentage of proliferative CD8 T cells exposed to BMDC cells with C16 CathSseq-SIINFEKL particles was even significantly higher than that of BMDC cells with C16 CathBseq-SIINFEKL.

[0222] Hybrid protein particles can induce T cell proliferation by releasing SIINFEKL (SEQ ID NO: 11) peptide. C16-CatS-SIIN particles are more effective than C16-CatB-SIIN particles.

[0223] Example 10: Hybrid spider silk particles accumulate in draining lymph nodes in vivo For in vivo biodistribution studies, particles were injected into the flank of mice, and 24 hours later, the mice were sacrificed and organs were harvested for analysis.

[0224] Female C57BL / 6JRj (Janvier, France) and OVA-TCR transgenic OT-I mice (Charles River, Germany) were housed under specific pathogen-free conditions and used at 6-12 weeks of age. Animal experiments were performed in accordance with the Swiss Federal Law on Animal Experiments.

[0225] C57BL / 6JRj mice were subcutaneously injected with 505 μg FITC-labeled C16-CathSseq-SIINFEKL particles in 100 μL PBS per mouse in the right flank of three mice. PBS was used as a negative control. After 24 h, ipsilateral inguinal draining lymph nodes (DLN), contralateral inguinal (non-DLN), and spleen were isolated for flow cytometry analysis and single cell suspensions were made as described above. Dead cells were excluded using Violet Zombie dye (Biolegend, USA). After Fc receptor blocking, the following antibodies were added: PerCP-CD3, Pe-Cy7-CD11b, APC-CD11c (all from Biolegend, USA).

[0226] FIG. 5A shows the number of FITC-positive cells (containing FITC-labeled C16-CathSseq-SIINFEKL particles) in the draining lymph nodes (DLN) of three FITC particle-treated mice compared to a control group of three PBS-treated mice in several tissues (DLN, non-DLN, and spleen).

[0227] Analysis showed that cathepsin S linker particles (C16-CathSseq-SIINFEKL) accumulated in local lymph nodes, preferentially in dendritic cells, but not in non-DLN cells or in the spleen. During surgery for organ harvest, the particles remained at the site of injection. C16 hybrid particles formed a depot under the skin and preferentially accumulated in local lymph nodes.

[0228] Figure 5B shows the uptake of cathepsin S linker particles (C16-CathSseq-SIINFEKL) only in dendritic cells (CD11c+CD11b+) as opposed to monocytes / macrophages (CD11c-CD11b+). Dendritic cells are the most potent class of antigen presenting cells. If antigen presentation occurs in local lymph nodes, the particles will not diffuse uncontrollably throughout the body.

[0229] Example 11: SIINFEKL-containing spider silk particles induce antigen-dependent T cell proliferation in vivo In vivo T cell expansion After CD8+ T cell isolation from OT-I splenocytes, cells were stained with CFSE in the absence of FCS according to the manufacturer's protocol. 6 CFSE-labeled CD3+CD8+ OT-I cells were injected intravenously into mice. 18 hours later, mice were immunized subcutaneously with 505 μg C16 and C16-CathSseq-SIINFEKL particles (505 μg particles in 100 μL PBS per mouse). R848 (25 μg in 100 μL) was used as an adjuvant. PBS without hybrid particles and R848 adjuvant served as negative controls. Three days after vaccination, inguinal DLNs were isolated for flow cytometry analysis to determine the proliferation of CD3+CD8+ CFSE-labeled OT-I cells. Single cell suspensions were obtained by passing through a 20 μm cell strainer. After Fc receptor blocking, the following antibodies were added: PB-CD3, APC-Cy7-CD8 (all from Biolegend, USA). Proliferation was assessed by measuring the CFSE-dependent increase in the CD3+CD8+ cell population. DIM It was determined by the percentage of cells.

[0230] statistical analysis All graphs were generated with GraphPad prism software version 6.0g (GraphPad Software, San Diego, USA) and error bars indicate standard error of the mean (SEM). Statistical significance of multiple groups versus the control group (untreated samples) was performed using one-way ANOVA followed by Dunnett's multiple comparison test.

[0231] Figure 6 shows the proliferation of CD8 T cells in mice immunized with C16-CathSseq-SIINFEKL particles. The proliferation of CD8 T cells was significantly higher without the R848 adjuvant. Immunization with C16-CathSseq-SIINFEKL without adjuvant resulted in a similar, respectively higher proliferation of CD8 T cells than immunization with C16-CathSseq-SIINFEKL with adjuvant. This was unexpected since the immune response is usually higher after the co-administration of an immunostimulatory adjuvant.

Claims

1. A particle formed by a polypeptide, comprising: The polypeptide, (i) a spider silk polypeptide comprising at least two repeating units, said repeating units being independently selected from the group consisting of a module C having a sequence according to SEQ ID NO: 3 or a variant having at least 94% sequence identity thereto, a module C Cys having a sequence according to SEQ ID NO: 4 or a variant having at least 94% sequence identity thereto, and a module C kappa having a sequence according to SEQ ID NO: 18 or a variant having at least 94% sequence identity thereto, (ii) antigenic peptides or polypeptides for therapeutic or pharmacological use, and (iii) Cathepsin S cleavable linker Including, A particle, wherein the antigenic peptide or polypeptide is linked to the spider silk polypeptide comprising at least two repeating units via the cathepsin S cleavable linker.

2. The particle described in claim 1, wherein the cathepsin S cleavable linker has a sequence according to SEQ ID NO: 1 or a sequence having at least 90% sequence identity thereto, or a sequence according to SEQ ID NO: 2 or a sequence having at least 90% sequence identity thereto.

3. 3. The particle of claim 1 or claim 2, wherein the spider silk polypeptide is a recombinant spider silk polypeptide.

4. 4. The particle of claim 1, wherein the particle has a negative surface charge.

5. 5. The particle according to claim 1, wherein the particle has an average diameter in the range of from 50 nm to 1000 nm.

Citation Information

Patent Citations

  • CH-4010

  • Compositions that induce T cell help

    JP2013503159A

  • Silk particles for controlled and sustained delivery of compounds

    JP2013512265A

  • Production of proteins and polypeptides

    JP2013521801A

  • Targeted multiepitope formulations that induce an immune response against an antigen.

    JP2013538211A